Capsule Endoscopy in Inflammatory Bowel Disease: A Systematic Review

Abstract

The role of video capsule endoscopy (VCE) in inflammatory bowel disease (IBD) has evolved from small bowel to a panenteric evaluation tool over the past two decades. We systematically reviewed the techniques, applications, outcomes, and complications of VCE in IBD. A systematic literature search was performed using PubMed, Embase, and Medline. All relevant original articles involving VCE in IBD were included from 2003 to July 2022. After screening 3,089 citations, finally 201 references were included. The diagnostic yield of VCE in suspected Crohn's disease (CD) was highly variable (6–80%) with excellent sensitivity (77–93%) and specificity (80–89%). The diagnostic yield in known CD was 52 to 88.3% leading to a change in management (26–75%) and disease reclassification with variable retention rates. VCE was superior to small bowel series, computed tomography (CT) and could be better than magnetic resonance enterography (MRE), especially for proximal and superficial lesions. Colon or panenteric VCE has strong correlation to ileo-colonoscopy (IC) and combined magnetic resonance imaging and IC, respectively. The VCE retention rate in CD is higher in known CD which significantly decreases after the negative patency capsule test or CT/MRE. VCE can identify lesions beyond the reach of IC in postoperative CD. Colon Capsule Endoscopy is a noninvasive monitoring tool in ulcerative colitis (UC) having a strong correlation with IC and may uncover small bowel involvement. VCE is specifically useful in IBD-unclassified (IBD-U) which can lead to the diagnosis of CD in 16.7 to 61.5%. Various scoring systems have been established and validated for small bowel CD (Lewis score and capsule endoscopy CD activity index—CECDAI), UC (capsule scoring of UC: Capsule Scoring of Ulcerative Colitis), panenteric evaluation (Capsule Endoscopy Crohn's Disease Activity Index, Elaikim score), and flare prediction (APEX score). Technological advances include double head, three-dimensional reconstruction, sampling system, panoramic view (344 and 360 degree lateral), and panenteric capsule. Artificial intelligence and software like TOP100 and Quickview can help reduce capsule reading time with excellent sensitivity and specificity. VCE in IBD has widespread application in suspected and known small bowel CD, monitoring of UC, postoperative CD, IBD-U, and for panenteric evaluation. Patency capsule testing helps to reduce retention rates significantly. Artificial intelligence and technical advances can help evolve this novel technology.

 

MissingLinkText

Keywords

video capsule endoscopy - Crohn's disease - ulcerative colitis - inflammatory bowel disease - patency capsule

Introduction

Video capsule endoscopy (VCE) is a noninvasive, widely available, nonoperator-dependent imaging modality in inflammatory bowel disease (IBD) which avoids any radiation exposure and, hence, has high patient acceptability.[1] [2] Although initially developed for detecting small bowel disease, the role of VCE has evolved to panenteric evaluation.[3] The role of VCE in postoperative Crohn's disease (CD) and treatment follow-up is being increasingly recognized. The drawbacks include risk of retention and inability to procure biopsy and to detect extraluminal disease.[4] The risk of retention can be substantially reduced by the use of patency capsule testing. A new recoverable sampling system (RSS) has shown the technical feasibility of obtaining biopsy with capsule technology, however still not in routine clinical use.[5] As newer methods of deep small bowel total enteroscopy like novel motorized spiral enteroscopy have evolved parallel to the development of capsule endoscopy, the positioning of VCE in the evaluation of IBD needs reconsideration.[6] Hence, we systematically reviewed the literature to understand the current role of VCE in evaluation and monitoring of IBD.

 

MissingLinkText

Materials and Methods

Search Strategy

Data Sources

For the purpose of the review, we used the PubMed, Embase, and Medline databases.

 

MissingLinkText

Study Selection

All relevant original research articles involving VCE in IBD were included for the review from 2003 to July 2022.

 

MissingLinkText

Interventions

We intended to evaluate the current role of VCE in the evaluation and monitoring of IBD. We included articles using keywords such as capsule endoscopy, inflammatory bowel disease, Crohn's disease, ulcerative colitis, indeterminate colitis, panenteric capsule, artificial intelligence, postoperative Crohn's recurrence, patency capsule, Lewis score (LS), and capsule endoscopy Crohn's disease activity index.

 

MissingLinkText

Main Outcome Measures

The role of VCE in suspected and known CD, ulcerative colitis, postoperative CD recurrence, IBD-unclassified (IBD-U), pouchitis, role of various scoring systems, role of artificial intelligence, and technological advances were assessed.

 

MissingLinkText

Results

We screened total 3,089 citations and 502 were screened for full test after the exclusion of articles based on title and abstract and exclusion of duplicates. Finally, 201 citations were included for our review excluding case reports/series/original articles with a small sample size (less than 10 subjects unless they are addressing special circumstances/describing novel technique or an unique complication)/letter to editor/editorials/conference abstracts ([Fig. 1]) and including relevant articles with specific searches and selected cross references.

Fig. 1 Search strategy for systematic review.

 

MissingLinkText

Limitations

The limitations include a qualitative review of all study types given the paucity of controlled or comparative studies and preexisting meta-analysis of prospective studies in a few aspects.

 

MissingLinkText

 

MissingLinkText

 

MissingLinkText

Results

Role of Video Capsule Endoscopy in Inflammatory Bowel Disease

Video Capsule Endoscopy in Suspected Crohn's Disease

Study Selection and Study Characteristics

We have identified 30 original articles (13 prospective) which evaluated the role of VCE in suspected CD[7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] ([Table 1]).

Table 1 Summary of studies evaluating role of video capsule endoscopy in suspected Crohn's diseases

Author	Indication	Study type	N	Diagnostic yield	Sensitivity	Specificity	PPV	NPV	Adverse events
Fireman et al 2003[7]	Suspected CD, negative conventional imaging	Prospective	17	71%	–	–	–	–
Herrerías et al 2003[8]	Suspected CD, negative conventional imaging	Prospective	21	43%	–	–	–	–	None
Ge et al 2004[10]	Suspected CD, negative conventional imaging	Prospective	20	65%	–	–	–	–	–
De Bona et al 2006[12]	Suspected CD, negative conventional imaging	Prospective	38	39.5% (46.2%with symptoms+ biochemical markers of inflammation)	–	–	–	–	2.6%
van Tuyl et al 2006[13]	Suspected small bowel disorders including CD	Retrospective	57	49%	–	–	61%	92%	–
May et al, 2007[15]	Abdominal pain+ diarrhea weight loss/anemia/elevated inflammatory markers	Prospective	50	54% Additional symptom increased diagnostic yield	–	–	–	–	Retention (4%)
GIrelli et al 2007[14]	Suspected CD: pain and diarrhea >3 mo + fever/weight loss/anemia/EIM	Prospective	27	59%	93%	84%	–	–	Retention requiring surgery (11.1%)
Tukey et al 2009[18]	Suspected CD or pain and/or diarrhea	Retrospective	102	37% (13% final diagnosis of CD on follow up)	77%	89%	50% (depends on selection criteria)	96%	–
Figueiredo et al 2010[19]	Suspected CD	Retrospective	78	39.8% (56% for those with negative ileoscopy)	93%	80%	77%	94%	Retention (4%)
Adler et al 2012[21]	Perianal disease, normal ileo-colonoscopy/SBFT/CTE/MRE	Prospective	26	24%	–	–	–	–	0%
Kalla et al 2013[24]	Suspected CD	Retrospective	265	12%	–	–	–	–	–
Egnatios et al 2015[27]	Chronic abdominal pain	Retrospective	90	24.4% (27.1% with additional symptoms, 19.4% only pain)	–	–	–	–	None
Mitselos et al 2016[29]	Chronic abdominal pain and/or diarrhea	Retrospective	91	17.6%	63.6%	92.5%	–	–	–
Lee and Lim 2016[28]	Symptomatic patients with Isolated ileitis	Retrospective	137	85.4% (high with ileal ulcer/erosion and high ESR)	–	–	–	–	–
Song et al 2017[30]	Chronic diarrhea	Retrospective	91	42.9% (hematochezia and hypoalbuminemia were predictors)	–	–	–	–	1%
Huang et al 2018[32]	Chronic abdominal pain >3 mo	Retrospective	341	28.15% (33.3% for abdominal pain + associated symptoms) (half had inflammatory pathology)	–	–	–	–	0%
Magalhaes et al 2019[33]	Suspected CD	Prospective	220	44.5% (high CRP, low iron increased yield)	–	–	–	–	–
Min et al 2013[25]	Suspected CD (pediatric)	Retrospective	17	6%	–	–	–	–	0%
Gralnek et al 2012[23]	Suspected CD (pediatric)	Prospective	10	80%	–	–	–	–	0%
Argüelles-Arias et al 2004[9]	Suspected CD (pediatric, ≥12–16 y)	Prospective	12	58.3%	–	–	–	–	0%
Wu et al 2020[34]	Symptomatic patients (abdominal pain, obscure GI bleed, diarrhea etc.) (Pediatric)	Retrospective	825	19.9% CD	–	–	–	–	Retention requiring surgery (0.4%)
Nuutinen et al 2011[20]	Suspected CD (pediatric) (8–188 mo)	Retrospective	26	62%	–	–	–	–	0%
Moy and Levine 2009[17]	Suspected CD (pediatric) (growth failure)	Retrospective	7	57.1% Improvement in height after small bowel CD treatment	–	–	–	–	1 retained in stomach
Cohen et al 2012[22]	Suspected CD (pediatric)	Retrospective	184	15%	–	–	–	–	1 retention
Esaki et al 2014[26]	Suspected CD	Retrospective	80	72.5%	–	–	–	–	6.3% retention
van Tuyl et al 2007[16]	Suspected CD	Retrospective	22	71% definitive diagnosis, 14% probable diagnosis	–	–	–	–	–
Mow et al 2004[11]	Suspected CD	Retrospective	8	37.5%	–	–	–	–	12.5%
Eliakim et al 2018[31]	Suspected CD (panenteric capsule)	Prospective	7	57.1%	–	–	–	–	None
Broderson et al 2022[36]	Suspected CD (panenteric capsule)	Prospective	59	44.8% Better image quality with increased volume of PEG but no change in diagnostic yield (43.9% versus 47.1%)	–	–	–	–	Not mentioned clearly
Tai et al 2020[35]	Suspected CD (panenteric capsule)	Prospective	22	13.6%	–	–	–	–	0%

Abbreviations: CD, Crohn's disease; CRP, c-reactive protein; ESR, erythrocyte sedimentation rate; NPV, negative predictive values; PEG, polyethylene glycol; PPV, positive predictive values.

 

MissingLinkText

Results

Suspicion of CD is the most common indication of VCE in IBD as per a Spanish physician survey.[37] The diagnostic yield was highly variable (6–80%) across these studies. This wide variability can be explained by the heterogeneity of study design, variable definitions of suspected CD, pretest probability in the subjects studied, and variable age groups (includes pediatric). The probability was higher with an increasing number of symptoms, elevated biochemical markers of inflammation, anemia, and hypoalbuminemia.

Three studies evaluated the sensitivity and specificity of VCE which were excellent (77–93% and 80–89%, respectively). The positive predictive values (PPVs) and negative predictive values (NPVs) varied from 50 to 77% and 92 to 96%, respectively. VCE retention rates varied from 0 to 12.5%. Two meta-analyses have shown that VCE was superior to small bowel follow through (SBFT) and ileo-colonoscopy (IC) and comparable to computed tomography enterography (one meta-analysis showed inferiority to VCE and another comparable to VCE)/MRE in the evaluation of suspected CD (see comparative yield section).[38] [39]

 

MissingLinkText

3.1.1. Capsule Endoscopy Differentiating Crohn's Disease from Mimics (e.g., Small Bowel Tuberculosis)

Capsule endoscopy findings should be interpreted in correlation with other findings to differentiate from other similar appearing lesions like small bowel tuberculosis (SBTB), nonsteroidal anti-inflammatory drugs enteropathy, Behcet's disease, vasculitis, and also normal variation (10%). In a prospective study, out of 37 suspected CD patients on VCE, only 13% were subsequently diagnosed to have CD on 1 year follow-up.[18] On the contrary, 19% patients with nonspecific enteritis develop CD on follow-up. High baseline LS (>135) and clinical suspicion were predictors of the subsequent development of CD.[40]

To address the aforementioned issue, a prospective study from India in which VCE was done in 26 patients after proving bowel patency showed that ileo-cecal valve involvement and aphthous ulceration were universal in SBTB (100% compared with 33% in CD) and CD (100% compared with 25% in SBTB), respectively. Large ulcers were more common in SBTB as compared with CD (75 vs. 47%).[41]

 

MissingLinkText

3.1.2. Factors Affecting Yield of Video Capsule Endoscopy in Suspected Crohn's Disease

Based on clinical symptoms, the combination of abdominal pain and diarrhea was shown to be highly predictive of CD on VCE. Nearly, one-third with the combination of symptoms had CD in this retrospective analysis.[42] The diagnostic yield with only chronic abdominal pain was 20.9% based on a systematic review.[43] The independent predictive factors of proximal small bowel involvement were ileal involvement, stricturing behavior, and significant weight loss.[44] In suspected CD with negative IC and SBFT, the combination of anemia and increased platelet count was a significant predictor of CD on VCE.[45] Fecal calprotectin as a predictor of the lesion in VCE has shown variable results in several studies with variable cutoffs.[46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60]

Fecal calprotectin level >194 μg/g had a sensitivity and specificity of 47 and 90%, respectively, for diagnosing CD on VCE.[57] On the contrary, fecal calprotectin <50 μg/g had a negative predictive value of 91.8% of having CD on VCE based on a systematic review.[52]

Two studies have evaluated multiple parameters for the prediction of CD. A Spanish multicenter study developed and validated a scoring index based on fecal calprotectin (score 10), c-reactive protein (CRP; score 6), thrombocytosis (score 3), anemia (score 2), leukocytosis (score 2), and high erythrocyte sedimentation rate.[1] Score ranges 0 to 5, 6 to 15, and ≥16 predicted low, intermediate, and high risk of inflammatory lesions on VCE, respectively.[61]

Another elegant study has shown the incremental yield of VCE with an increasing number of International Conference on Capsule Endoscopy (ICCE) criteria. Suspected CD was defined as clinical symptoms (chronic abdominal pain/diarrhea, weight loss, and growth failure) plus any one or more extraintestinal manifestations, inflammatory markers, and abnormal imaging (SBFT/CTE). The prevalence of CD in those with suspected CD not supported by ICCE criteria, two criteria, and three criteria was 21.4, 52.6, and 77.8%, respectively. In those with LS ≥135, 82.6% had CD.[62]

 

MissingLinkText

3.1.3. Value of Repeat Video Capsule Endoscopy in Suspected Crohn's Disease

In a letter to the editor, Robertson et al have reported findings of 18 patients with suspected CD who underwent repeat VCE on follow-up. Those with nonspecific inflammation on initial VCE (33%) were more likely to have repeat VCE suggestive of CD (33%) along with those with higher fecal calprotectin levels.[63]

 

MissingLinkText

3.1.4. Role of Video Capsule Endoscopy in Presymptomatic Patients

VCE has been used in first-degree relatives of CD patients to identify those with subclinical small bowel inflammation. A cross-sectional study in 2017 by Teshima et al showed increased intestinal permeability, and small bowel ulceration (≥3) was seen in 30 and 24% of the first-degree relatives (n = 223) with CD. However, increased intestinal permeability did not correlate with small bowel inflammation.[64] Later, another study by Taylor et al in 2019 involving 480 asymptomatic first-degree relatives of CD has shown a risk tool comprising family history of CD, genetic variants associated with CD, and high level of fecal calprotectin predicted risk of presymptomatic small bowel inflammation.[65]

 

MissingLinkText

Role of Video Capsule Endoscopy in Spondyloarthropathy

Three prospective studies have shown a high yield of VCE (12.5–42.2%) to diagnose CD in the established case of spondyloarthropathy (SpA) with bowel symptoms.[66] [67] [68] Elevated fecal calprotectin (>100 µg/g) was the predictor of small bowel CD (odds ratio = 4.5).[68] In a case series of three juvenile idiopathic arthritis, all cases were diagnosed to have CD.[69]

 

MissingLinkText

 

MissingLinkText

Video Capsule Endoscopy in Known Crohn's Disease

Study Selection and Study Characteristics

A total of 29 original articles were identified (12 prospective) evaluating the role of VCE in known CD.

 

MissingLinkText

Results

Overall diagnostic yield varied from 52 to 88.3%. The yield was high for symptomatic CD (highest for diarrhea—73%), whereas it was 21.1 and 4.7% only in those with clinical remission and clinico-biochemical remission, respectively.[16] [20] [22] [23] [24] [25] [26] [31] [35] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] The incremental yield over SBFT was 32 to 32.7% and 7% over IC. In a prospective study in pediatric CD, the diagnostic yield of VCE (41%) was higher than magnetic resonance imaging (MRI)/small intestinal contrast ultrasonography (SICUS; 18.2%).[75] The incremental yield in the proximal small bowel was 28 to 50%.[23] [83] [85] The overall change in management after VCE varied from 21 to 71% which included treatment escalation, deescalation, initiation of new medications (biologics/immunomodulators), and decision for surgery.[16] [24] [85] [87] Other implications of VCE in known CD are reclassification of disease phenotype (11%), assessment of mucosal healing posttherapy, and prediction of relapse (higher with jejunal disease).[78] [82] [84] Clinical and biochemical improvement can predict mucosal healing in less than half (none at 2 weeks, 42% at 52 weeks) of the patients.[89] [90] [91] The rate of retention varied from 2.1 to 18.6% ([Table 2]).

Table 2 Summary of studies evaluating role of video capsule endoscopy in known Crohn's diseases

Author	Indication	Study type	N	Yield/Incremental yield	Impact on management	Adverse events/retention
Cotter et al 2014	Known CD	Retrospective	50	Incremental yield- 66%	Initiation of immunomodulators/biologics increased by 26%	6% retention
Dussault et al 2013	Known CD	Retrospective	77	Overall yield - 62%	53.5% 60% in unexplained anemia 58% when performed for assessing disease location 20% when performed for discordance between symptoms and morphology	4.2% transient retention after negative patency testing
Elosua et al 2022	Known CD	Retrospective	432	Overall yield - 63.7%	51.4%, Escalation- 46.1%, De-escalation-5.3% Escalation:89.5% in moderate-severe disease, 57.8% mild disease	2.5% retention, all managed nonsurgically
Flamant et al 2013	Known CD	Retrospective	108	Jejunal lesions -56%	Increased risk of relapse with jejunal lesions	5.5% retention
Hansel et al 2018	Known CD	Prospective	50	Proximal small bowel incremental yield- 28%	Altered management- 34% New medication initiated- 29% Exclusion of active small bowel disease- 24%	None reported except dysphagia in one
Kopylov et al 2015	Known CD	Retrospective	187	Overall yield- 71.6%	52.3%	Retention 2.1%
Mehdizadeh et al 2010	Known CD	Retrospective	134	Overall yield - 52% (highest for diarrhea -73%) Incremental yield- 32% (to SBFT) 7% (to IC)	Not evaluated	None
Melmed et al 2018	Known CD	Prospective	53	Proximal small bowel -85%	Not evaluated, high correlation with IC No correlation with clinical severity indices (CDAI)	None were capsule related
Niv et al 2014	Known CD	Prospective	19	78.9% at week 0 84.6% at week 4	Not evaluated, No correlation with sequential clinical severity indices (CDAI)	No retention
Park et al 2007	Known CD	Retrospective	52	32.7% (over-SBFT)	28.8%	Retention-9.6% Surgery- 3.8%
Petruzziello et al 2010	Known CD	Prospective	32	50% (in CD involving distal ileum)	Not evaluated	3% retention
Santos-Antunes et al 2015	Known CD	Retrospective	106	Proximal small bowel -46% (incremental yield)	40% Immunomodulator therapy post-VCE 44 vs. 21% pre VCE	None
Lorenzo-Zu ́n ̃iga et al 2010	Known CD	Prospective	14	85.7%	64%	None
Long M et al 2011	Known CD, indeterminate colitis and pouchitis	Retrospective	86 (CD)	77.9%	Change in medication: 51.1% New IBD medication: 39.5% Surgery: 12.8%	16 cases of retention 8 required operative intervention
Nardo et al 2011	Known pediatric CD	Prospective	44	41% with VCE vs. 18.2% with MRI/SICUS	Not evaluated	None
Kalla et al 2013	Known CD	Retrospective	50	66%	Management was altered in 48%	None
Greener et al 2016	Known CD	Prospective	56	51%	Reclassification of disease phenotype in 11%	1 patient had temporary patency capsule retention
Min et al 2013	Known pediatric CD	Retrospective	50	70% (43% extensive disease compared with other imaging)	75% Improved growth, BMI, HBI, and ESR on follow-up	None
Gralnek et al 2012	Known pediatric CD	Prospective	4	50% more proximal involvement detected	75% change in management	None
Oliva et al 2019	Known pediatric CD	Prospective	48	71% (panenteric capsule endoscopy)	71% change in management Mucosal healing achieved at 24 and 52 wk were 54 and 58% respectively compared with 21% at baseline	No serious event except for nausea and vomiting in 3 patients
Nuutinen et al 2011	Known pediatric CD	Retrospective	9	56%	–	1 had retention requiring elective surgery
Cohen et al 2012	Known pediatric CD	Retrospective	61	57.3%	–	9.8%
Cohen et al 2008	Known pediatric CD	Retrospective	21	62%	23.8% change in management	1 had retention
Esaki et al 2014	Known CD	Retrospective	94	88.3%	75% (8/12) of colonic disease reclassified as ileo-colonic disease	7.4% retention
Tuyl et al 2007	Known CD	Retrospective	14	71% definitive diagnosis 14% probable diagnosis	21% changed management	None
Mow et al 2004	Known CD	Retrospective	20	70%	60%	5% retention
Eliakim et al 2018	Known CD	Prospective	29	55.17% (panenteric capsule) 31% proximal disease	Not evaluated	None
Tai et al 2020	Known CD	Prospective	71	67.6%	38.7% had change in management Upstaging of Montreal classification 33.8% Mucosal healing 15.5%	2.8%
Kopylov et al 2015	Known CD (clinical remission or mild symptoms)	Prospective	56	21.1% in those in clinical remission 4.7% in clinico-biochemical remission	Mucosal healing and deep remission are rare in CD in clinical remission and hence may require escalation of therapy	0%

Abbreviations: BMI, body mass index; CD, Crohn's disease; CRP, c-reactive protein; ESR, erythrocyte sedimentation rate; HBI, harvey bradshaw index; MRI, magnetic resonance imaging; NPV, negative predictive values; PEG, polyethylene glycol; PPV, positive predictive values; SBFT, small bowel follow through; SICUS, small intestinal contrast ultrasonography; VCE, video capsule endoscopy.

 

MissingLinkText

 

MissingLinkText

3.3. Video Capsule Endoscopy Compared with Other Imaging Technologies in Suspected or Known Crohn's Disease

Study Selection and Study Characteristics

In total, 9 studies including 378 patients compared the diagnostic yield of VCE with various other modalities (IC, SBFT, CTE, MRE, SICUS) in suspected CD.

 

MissingLinkText

Results

VCE was better than all the other modalities with regard to diagnostic yield except MRE ([Table 3])[29] [92] [93] [94] [95] [96] [97] [98]. An earlier meta-analysis and a recent meta-analysis have also shown the same for both suspected and established CD.

Table 3 Video capsule endoscopy compared with other diagnostic modalities in suspected and known Crohn's disease

Author	Study type	N	Indication	Diagnostic yield	Comparator	Diagnostic yield of competing technology
Eliakim et al 2002	Prospective	20	Suspected CD	70%	Barium meal follow through (BMFT) Entero-CT	BMFT: 37% EnteroCT: 50%
Di Nardo eta 2010	Prospective	18	Suspected IBD	50%	MRI and/ or SICUS	22.2%
Eliakim et al 2004	Prospective	35	Suspected CD	77%	Barium meal follow through (BMFT) Entero-CT	BMFT: 23% EnteroCT: 20%
Voderholzer et al 2004	Prospective	41	Known CD	60.9	CTE	29.2%
Albert et al. 2005	Prospective	27	Suspected CD (n = 14) + known CD (n = 13)	93%	MRI Fluoroscopic enteroclysis	MRI: 78% Enteroclysis: 33%
Chong et al 2005	Prospective	43	Suspected CD (n = 21) + known CD (n = 22)	Suspected CD:19% Known CD 77% Change in management 70%	Push enteroscopy Enteroclysis	Enteroclysis (19% known CD, 6% suspected CD) Push enteroscopy: 16% known CD, 0% suspected CD)
Marmo et al 2005	Prospective	31	Known CD	71% 89% (with terminal ileal involvement) 46% (proximal small bowel)	Enteroclysis	25.8% 37% (with terminal ileal involvement) 13% (proximal small bowel)
Hara et al 2006	Prospective	17	Suspected CD	71%	IC CTE SBFT	IC: 65% CTE: 53% SBFT: 24%
Efthymiou et al 2008	Prospective	55	Suspected CD (n = 26) + known CD (n = 29)	Suspected CD:65% Known CD 74.1%	Enteroclysis	Enteroclysis (3% suspected CD, 40.7% known CD) (p < 0.05)
Solem et al 2008	Prospective	28	Suspected CD + known CD	Sensitivity:83% Specificity:53%	CTE IC SBFT	CTE Sensitivity: 67% Specificity:100% (p = 0.02) IC Sensitivity:67% Specificity:100% (p = 0.03) SBFT Sensitivity:50% Specificity:100% (p = 0.2)
Bocker et al 2010	Prospective	21	Suspected or known CD	42.9%	MRI	28.6%
Petruzziello et al 2010	Prospective	30	Suspected CD	50% Incremental yield: 33%	IC SICUS SBFT	IC: 63% SICUS: 40% SBFT: 50%
Casciani E et al 2011	Prospective	37	Pediatric suspected CD	Sensitivity: 97.6% Specificity: 92.3% Accuracy: 98.3%	MRE	Sensitivity: 91.9% Specificity: 90.9% Accuracy: 100%
Jensen et al 2011	Prospective	93	Suspected or newly diagnosed CD	Sensitivity: 100% Specificity: 91% (terminal ileum)	CTE MRE	CTE Sensitivity: 76% Specificity: 85% MRE Sensitivity: 81% Specificity: 86%
Wiarda et al 2011	Prospective	38	Suspected CD (n = 20) + known CD (n = 18)	Sensitivity: 57% Specificity: 89% PPV: 67% NPV: 84%	MRE	Sensitivity: 73% Specificity: 90% PPV: 88% NPV: 78%
Kovanlikaya et al 2013	Retrospective	23	Children with suspected or known IBD	Sensitivity 77.8%	MRE	Sensitivity: 75%
Aloi M et al, 2014	Prospective blinded, comparative	25	Pediatric suspected CD (n = 6) + known CD (n = 28)	Sensitivity in jejunum, proximal /midileum and terminal ileum were 92, 100, and 81%, respectively	MRE SICUS	Sensitivity: MRE: jejunum: 75%, Proximal/mid ileum: 100%, terminal ileum: 81% SICUS: jejunum: 92%, Proximal/mid ileum: 80%, terminal ileum: 94% Specificity of capsule lower in jejunum (61%) and proximal/mid ileum (74%) but higher in terminal ileum (90%)
Leighton et al 2014	Prospective	80	Suspected small bowel CD	VCE + IC (small bowel + colon)- 97.3% VCE (terminal ileum+ cecum) - 49.2% VCE (small bowel)- 93%	1. IC (terminal ileum + cecum) 2. SBFT + IC (small bowel + colon) 3. SBFT (small bowel)	1. IC (terminal ileum + cecum) −70.5% (p = 0.09) 2. SBFT+ IC (vs. IC + VCE) − 57.3% (p < 0.001) 3. SBFT (small bowel) (vs. VCE) − 25.6%
Oliva et al 2015	Prospective	40	Pediatric known CD	Colon Sensitivity: 89% Specificity:100% PPV: 100% NPV: 91% Small bowel Sensitivity: 90% Specificity: 94% PPV: 95% NPV: 90%	SICUS MRE	SICUS (small bowel) Sensitivity: 90% Specificity: 93% MRE (small bowel) Sensitivity: 85% Specificity: 89%
Leighton et al 2016	Prospective	114	Known active CD with proven bowel patency	Panenteric capsule endoscopy: 83.3%	IC	69.7%
Mitselos et al 2016	Retrospective	91	Suspected CD	Sensitivity: 81.82% Specificity: 77.50% PPV: 53.85% NPV: 94.87% AUC: 0.781	IC	Sensitivity: 63.64% Specificity: 92.50% PPV: 33.33% NPV: 96.88% AUC: 0.797
Carter D et al, 2018	Prospective	50	Suspected CD- negative ileocolonoscopy	38%	IUS	38%, Sensitivity: 72%, specificity: 84% compared with capsule endoscopy which was considered gold standard
Gonzalez-Suarez et al 2018	Prospective	47	Suspected CD (n = 15) + known CD (n = 32)	76.6% (higher in jejunal, ileal and terminal ileal lesions)	MRE	44.7% (capsule significantly better for superficial and proximal lesions)
Hijaz et al 2019	Prospective	27	Children with CD or indeterminate colitis	Sensitivity: 83% Specificity: 78.6%	MRE	Sensitivity: 100% Specificity: 57.14% Capsule has lower sensitivity but high specificity
Bruining DH et al 2020	Prospective	99	Known CD (Panenteric capsule)	Sensitivity 94% (proximal small bowel 97%) Specificity: 74%	MRI + IC	Sensitivity: 100% Specificity: 22% (p = 0.021; similar specificity in terminal ileum and colon)
Yamada et al 2021	Prospective	20	Known CD, Colon capsule endoscopy	Diagnostic accuracy (detecting ulcers) Small bowel-88.3% Large bowel-78.1%	Bidirectional double balloon enteroscopy	Reference standard
Dubsenco et al 2005	Prospective	39	Known and suspected CD	Sensitivity: 89.6% Specificity-100.0%, Positive predictive value:100% Negative predictive value: 76.9	Small bowel series	Sensitivity: 27.6% Specificity: 100.0% PPV: 100.0% NPV: 32.3%.
D′Haens et al 2015	Prospective	40	Colonic CD (paneneteric capsule PCCE-2)	Sensitivity: 86% Specificity: 40%	Colonoscopy	Reference standard Better estimated the disease severity compared with PCCE-2 PCCE-2 better tolerated
Papalia et al 2021	Prospective	47	Known ileo-colonic, nonstricturing CD for mucosal healing	Strong correlation with SES-CD scores in colonoscopy (r = 0.77), strongest in terminal ileum	Colonoscopy	PCCE-2 identified additional ulcers PCCE-2 was complete in 68% cases compared with 89% colonoscopy PCCE-2 noninvasive modality for monitoring
Ben Horin et al 2019	Prospective	61	Clinically quiescent known CD for predicting flare	Lewis score >350 predicted risk of flare with AUC 0.79	Fecal calprotectin MRE	Fecal calprotectin (AUC) 2 y flare: 0,62 6 mo flare: 0.81 MRE risk prediction (AUC) 2 y:0.71

Abbreviations: AUC, area under the curve; CD, Crohn's disease; IC, ileo-colonoscopy; CTMRI, magnetic resonance imaging; IUS, intestinal ultrasound; MRE, magnetic resonance enterography; PCCE, panenteric colon capsule endoscopy; SES- CD, simple endoscopic score Crohn's disease; SICUS, small intestinal contrast ultrasonography.

Similar results were found in known CD (10 articles and 2 meta-analysis)[3] [99] [100] [101] [102] [103] [104] [105] [106] [107]. However, SICUS had comparable sensitivity (90%) and specificity (93%) to VCE for small bowel involvement in pediatric CD.[102] Panenteric colon capsule endoscopy (PCCE) has been compared with MRE plus IC and was found that MRE + IC had 100% sensitivity (94% with VCE) but low specificity (22% compared with 74% with PCCE).[106] PCCE has been compared with reference endoscopic standard (bidirectional double balloon enteroscopy), and diagnostic accuracy was 88.3 and 77.1% for small and large bowel, respectively.[3] Compared with colonoscopy, the sensitivity and specificity of CCE were 86 and 40%, respectively.[101] Moreover, risk prediction for future flare was better with the VCE LS (AUC—area under the curve: 0.79) compared with MRE risk prediction (AUC: 0.71). Among 11 studies (n = 439) comprising both suspected and known CD, VCE had higher sensitivity compared with CTE, IC, and SBFT but lower specificity (53% compared with 100% with others).[108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] Comparing the specificity of VCE according to the regions of small intestine, the specificity of VCE was lower in jejunum (61%) and proximal/mid-ileum (74%), but higher in terminal ileum (90%) compared with MRE and SICUS ([Table 3]).[117] VCE was better compared with MRE for proximal and superficial lesions.

 

MissingLinkText

 

MissingLinkText

3.4. Risk of Retention in Suspected or Known Crohn's Disease

The risk of retention of VCE is 13% in established CD and 1.6% in suspected CD based on the earlier retrospective study by Cheifetz et al.[119] The overall retention rate in CD is 3.32% (2.35% suspected CD and 4.63% known CD) based on an updated systematic review and meta-analysis.[120] This is the reason why VCE is not generally preferred in established CD except for patients with anemia, obscure GI bleed, or assessment of mucosal healing. Retention rates were lower in pediatric CD (1.64%) compared with adult CD (3.49%).[120]

3.4.1. Predictors of Capsule Retention

Negative patency capsule testing and negative CT/MRE are negative predictors of capsule retention. The retention rates of patency capsule varied between 15.2 and 28% in known CD.[121] [122] A retrospective study showed that the retention rates after positive and negative patency capsule testing were 11 and 2.1%, respectively.[123] Similarly a prospective study showed 28.9% retention rates with active inflammation on MRE.[122] Based on meta-analysis, the retention rates in established CD remained 2.88% even after patency capsule testing and 2.32% after CT/MRE. The risk of retention is reduced after CT/MRE by 50%. MRE has a sensitivity of 92.3% and specificity of 59% to evaluate capsule retention as compared with 97 and 83%, respectively, for patency capsules. MRE tends to overdiagnose the risk of capsule retention. If only MRE is used to predict retention instead of patency capsule, nearly 40% patients (specificity—59%) would not undergo VCE due to fear of capsule retention.[122]

Other predictors were obstructive symptoms, stricturing/penetrating disease, BMI≤ 5th percentile, suspected stenosis on SBFT, restricted diffusion on diffusion-weighted MRI, extensive small bowel thickening on small bowel ultrasound, longer stricture length and higher number of prestenotic dilatations, high CRP, and history of abdominal surgery according to several studies[119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] ([Supplementary Table S1], available in the online version).

 

MissingLinkText

3.4.2. Management of Retained Capsule

Capsule retention is asymptomatic in 85% which can be managed conservatively with enteroscopy-guided removal electively. Partial air complete small bowel obstruction occurs in the rest which requires endoscopic retrieval with or without balloon dilation. There are several reports of retrieval by double-balloon enteroscope (success rate 80–92%) and recently novel motorized spiral enteroscopy which can avoid surgery in the majority.[137] [138] [139] Moreover, it can help take surgical decisions as some of the patients may require surgery even after capsule removal for treating the underlying disease.

 

MissingLinkText

3.4.3. Other Complications of Video Capsule Endoscopy

Although known CD substantially increases the risk of capsule retention, other complications of VCE like swallow disorder, aspiration, and technique failure can be substantial and clinically important. However, we could not find specific citations pertaining to IBD with regard to this. Meta-analysis, which included IBD patients, showed that the pooled rates of aspiration, technical failure, and swallow disorders were 0, 0.94, and 0.75%, respectively.[140]

 

MissingLinkText

 

MissingLinkText

3.4. Video Capsule Endoscopy in postoperative Crohn's Disease

Study selection and study characteristics

Five prospective and one retrospective study including 313 patients have compared VCE with colonoscopy in postoperative CD ([Supplementary Table S2], available in the online version).

 

MissingLinkText

Results

Except for the one retrospective study,[141] all the studies concluded that the yield of VCE was higher than colonoscopy in detecting postoperative recurrence especially for proximal involvement out of the reach of the colonoscopy.[142] [143] [144] [145] [146] [147] Another prospective study has compared capsule endoscopy or no capsule endoscopy in postoperative settings and has shown that VCE arm had lower hospitalization or surgery[147] ([Supplementary Table S2], available in the online version).

 

MissingLinkText

 

MissingLinkText

3.5. Video Capsule Endoscopy in UC

Study Selection and Study Characteristics

In total, 14 prospective and 3 retrospective studies involving 612 patients have evaluated the role of VCE in ulcerative colitis (UC) ([Table 4]).[11] [20] [23] [31] [75] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159]

Table 4 Summary of studies evaluating role of video capsule endoscopy in ulcerative colitis

Author	N	Study type	Small bowel involvement	Correlation with colonoscopy	Cleanliness	Adverse events
Ye et al 2013	26	Prospective		Excellent correlation with extent and severity of UC	80%	None
Higurashi et al 2011	23 UC and 23 healthy volunteers	Prospective	57%, correlated with disease activity	Not studies	Not evaluated	None
Hisabe et al 2011	30	Prospective	36.6% (40% in active UC and 33% in postproctocolectomy) (extensive colitis, pouchitis and age <20 y are predictors)	Not evaluated	–	None
Hosoe et al 2013	42	Prospective	Not evaluated	Strong correlation with colonoscopy	<50% good or excellent cleansing level	None
Juan Acosta et al 2014	42	Prospective	3 out of 42 patients	Good correlation for severity and extent of inflammation	80%	None
Matsubayashi et al 2020	41	Prospective	Not evaluated	Capsule Scoring of Ulcerative Colitis (CSUC) better than fecal biomarkers for predicting relapse	Not mentioned	None
Meister et al 2013	13	Prospective	Not evaluated	Colonoscopy detected vessel vulnerability, granulated mucosa, mucosal damage and disease extension better than capsule endoscopy	90% good or fair	None
Okabayashi et al 2018	33	Prospective	Not evaluated	Good correlation with endoscopic indices of severity. Active disease had longer transit time with resultant poor acceptability	77.2% acceptable	5.1% from laxatives, 7.7% delayed excretion (> 24 hours)
Oliva et al 2014	30, Pediatric	Prospective	Not evaluated	High sensitivity (96%), specificity (100%), positive predictive value (100%), negative predictive value (85%)	62% adequate, 24% fair	None
Shi et al 2017	150	Prospective	Not evaluated	Good correlation (R = 0.64–0,67) for severity of mucosal inflammation (sensitivity: 97%)	66%	21% mainly related to bowel preparation, one serious adverse event due to retention by unexpected rectal tumor
Sung et al 2012	100	Prospective	Not evaluated	High sensitivity (89%), specificity (75%), positive predictive value (93%), negative predictive value (65%)	64% acceptable, 31% fair	No serious adverse events, all related to bowel preparation
Nardo et al 2011	29	Prospective	No incremental yield	Not evaluated	Not evaluated	None
Gralnek et al 2012	2	Prospective	50%, diagnosis changed to CD	Not evaluated	Not evaluated	None
Nuutinen et al 2011	21	Retrospective	4.8%	–	–	None
Cohen et al 2011	5	Retrospective	80% (UC with suspicion of CD)	–	–	None
Mow et al 2004	20	Retrospective	59%	Not evaluated	Not evaluated	None
Eliakim et al 2018	5	Prospective	40% (panenteric capsule)	Not evaluated	Not mentioned separately	None

Abbreviation: CD, Crohn's disease.

 

MissingLinkText

Results

Overall results indicate that VCE had an excellent correlation with colonoscopy for severity/extent of inflammation and is better than fecal biomarkers. Patient acceptability was better than colonoscopy. Small bowel involvement in UC with VCE is variable (4.8–80%) and is dependent on the pretest probability (80% for those with suspicion of CD in a small series).[11] [23] [31] [149] [150] [156] In postproctocolectomy cases, extensive colitis, pouchitis, and age less than 20 years were predictors of small bowel involvement.[150] Active UC was also a predictor of small bowel involvement (40% compared with overall 36.6%).[150] No adverse events are reported except those related to bowel preparation and one case of retention due to unexpected rectal tumor ([Table 4]).[157] Bowel preparation was acceptable in 62 to 90% cases ([Table 4]).

 

MissingLinkText

3.5.1. Role of Video Capsule Endoscopy in Pouchitis

A single-center prospective study has shown that all of the patients with chronic antibiotic refractory pouchitis have small bowel lesions from duodenum to ileum detectable on VCE which ranges from aphthous to deep, fissuring ulcers. None of the patients have any prior evidence of CD on review of surgical biopsy. These patients need to be followed up further, and the significance of such lesions is still unknown.[160] In a retrospective study, small bowel capsule endoscopy in pouchitis showed positive findings in 65.2%. Initiation of new IBD medications was noted in 56.5%, and small bowel resection was done in 4.4% following VCE.[76]

 

MissingLinkText

 

MissingLinkText

3.6. Video Capsule Endoscopy in Inflammatory Bowel Disease-Unclassified

Study Selection and Study Characteristics

VCE could be particularly helpful in the IBD unclassified subgroup, where up to 16.7 to 50% patients can be diagnosed with CD after undergoing VCE as per four retrospective and five prospective studies in 177 adult and pediatric patients ([Supplementary Table S3], available in the online version).[23] [24] [25] [75] [148] [161] [162] [163] [164]

 

MissingLinkText

Results

However, VCE can miss a diagnosis of CD as five of the aforementioned studies have shown that 0 to 16.7% patients develop CD on follow-up.[23] [148] [161] [162] [164] A change in existing treatment after CD diagnosis may not be necessary in all the patients as the reported change in treatment after CD diagnosis was seen in 0 to 100%.[24] [163] [164] A confirmed diagnosis of UC after exclusion of small bowel involvement in IBD-U can occur in 5.5 to 59.3%.[23] [161] [162] [163] [164] No change in diagnosis of IBD-U can occur in 0 to 75% cases ([Supplementary Table S3], available in the online version). LS >135 is a predictor of CD diagnosis with a sensitivity and specificity of 90 and 100%, respectively.[164]

 

MissingLinkText

 

MissingLinkText

3.7. Scoring Systems for Video Capsule Endoscopy

Scoring systems in VCE may help predict disease severity and disease course similar to conventional endoscopic scoring. There are various validated scores for small bowel, colon, and panenteric evaluation.

3.7.1. Lewis Score

Study Selection and Study Characteristics

Total 9 studies (2 prospective) including 811 patients evaluated the role of the LS alone.[62] [165] [166] [167] [168] [169] [170] [171] [172]

 

MissingLinkText

Results

LS was initially developed by Gralnek et al based on edema, ulceration, and stenosis in three tertiles with the establishment of cut-off values ([Table 5]; [Fig. 2]).[165] Later, the incremental number of ICCE criteria was found to be the predictive factor of significant inflammatory activity (LS > 135) on VCE.[62] LS ≥ 135 was shown to have a positive predictive value of 73.9%, and a score <135 had a negative predictive value of 91.8%.[168] Similar findings were seen in another validation study. A strong agreement was seen for global as well as for each tertile score in interobserver study.[166] Recent studies have evaluated the prognostic role of LS to predict CD-related emergency hospitalization and risk of cumulative relapse.[171] [172] Correlation of VCE with disease activity and small bowel transit time was weak in adults, whereas correlation with inflammatory markers was moderate in both pediatric age group and adults.[169] LS score correlates well with the MRE global score (r = 0.71) except the proximal LS score (r = 0.55).[170]

Fig. 2 Video capsule endoscopy in Crohn's disease. (A) Aphthous ulcers, (B) linear ulcer, (C) transverse hemicircumferential ulcer, (D) circumferential ulcerated stricture, (E) fibrotic stricture, and (F) mucosal edema.

Table 5 Summary of studies on video capsule endoscopy scoring systems

Author and year	Scoring system	Area of bowel	N	Study type	Study objective	Results
Granlek et al 2008	LS	Small bowel	44	Prospective	Development of scoring index	Based on villous edema, ulcer and stenosis in three tertiles, LS was developed, score <135: clinically insignificant,135–790: mild, ≥790: moderate to severe.
Rosa et al 2012	LS	Small bowel	56	Retrospective	Usefulness of LS in suspected CD as per the ICCE criteria	Patients with suspected CD based on one or more ICCE criteria were more likely have inflammatory activity (LS > 135) compared with those in whom none of the ICCE criteria were present (incremental increase with increase in the number of ICCE criteria)
Cotter et al 2015	LS	Small bowel	70	Retrospective	Interobserver agreement	Strong interobserver agreement in each tertile and global score (k = 0.852–0.960; p < 0.0001)
Monteiro et al 2015	LS	Small bowel	95	Retrospective	Diagnostic accuracy of the LS in patients with suspected CD undergoing capsule endoscopy	LS > 135 had an overall diagnostic accuracy of 83.2% with a sensitivity, specificity, positive predictive value, and negative predictive value of 89.5, 78.9, 73.9, and 91.8%, respectively for the diagnosis of CD.
De Castro et al 2015	LS	Small bowel	53	Retrospective	Assess prognostic value of the severity of inflammatory lesions quantified by the LS	Increased need for steroid (RR: 5) and hospitalization (RR: 13.7) on multivariate analysis
He et al 2017	LS	Small bowel	150 (30 pediatric)	Retrospective	Correlation of LS with disease activity, inflammatory markers and small bowel transit time (SBTT)	Correlation with disease activity: moderate (pediatric), weak (adults) Correlation with inflammatory markers: Moderate (both) Correlation with SBTT: none (pediatric), weak (adults)
Nishikawa et al 2019	LS	Small bowel	125	Retrospective	Predicting emergency hospitalization and clinical relapse	An LS of 264 was an useful cutoff value that could predict CD-related emergency hospitalization and cumulative risk of relapse (AUC: 0.92)
Nishikawa et al 2021	LS	Small bowel	102 (retrospective) + 66 (prospective)	Retrospective +prospective	Predicting emergency hospitalization and clinical relapse based on retrospective analysis followed by prospective validation	LS ≥ 270 or prognostic nutrition index (PNI) < 45 had a significantly higher risk of Crohn's disease-related emergency hospitalization. Additional treatment in these patients
Klang et al 2018	LS for validation of MRE global score	Small bowel	50	Prospective	Validation of MRE global score using LS and fecal biomarkers	Significant correlation of LS with global MRE score (r = 0.71, p < 0.001), the correlation of MRE global score with Proximal LS score (r = 0.55). Correlation with fecal calprotectin was higher with MRE global score compared with LS
Gal et al 2008	CECDAI	Small bowel	20	Prospective	Assessment and validation	Strong interobserver agreement (k = 0.87) Convenient, reliable and reproducible diagnostic and follow-up tool
Niv et al 2012	CECDAI	Small bowel	62	Prospective	Validation of CECDAI score	The correlation between endoscopists between different centers was good (r = 0.767)
Miyazu et al 2021	CECDAI	Small bowel	21	Prospective	To assess use of CECDAI to predict need of additional treatment for patients in clinical remission	CECDAI was useful in assessing requirement of additional treatment for CD patients in clinical remission (more in those with CECDAI ≥ 5.8)
Koulaouzidis et al 2012	LS and CECDAI	Small bowel	49	Retrospective	Comparison of correlation with fecal calprotectin with LS and CECDAI	In patients with fecal calprotectin <100 μg/g, correlation was better with LS compared with CECDAI. In patients with elevated fecal calprotectin (>100 µg/g), neither LS and CECDAI correlated with fecal calprotectin.
Omori et al 2019	CECDAI and LS	Small bowel	132	Retrospective	Compare the usefulness of CECDAI and LS	CECDAI better reflect the status and severity of intestinal inflammation than LS Those with high LS but normal CECDAI may reflect strictures rather than active inflammation
Ponte et al 2017	CECDAI and LS	Small bowel	53	Retrospective	To identify cut off values of CECDAI as corresponding to LS cut offs	LS threshold values of 135–790 in LS corresponds to CECDAI cutoff values of 7.7–10.3, both scores did not have any correlation to CRP or Harvey–Bradshaw index
Elaikim et al 2020	Elaikim score	Panenteric	41	Substudy of a RCT	Correlation with LS and reliability	Excellent interobserver agreement (k = 0.9) and strong correlation with calprotectin levels (r = 0.54) which was better than with LS (r = 0.32)
Niv et al 2016	CECDAIic	Small bowel and colon	10	Prospective	Extension of Niv score into colon to establish a new score for small bowel and colon	Concordance high (0.85 for small bowel and 0.77 for entire bowel) except for proximal small bowel and distal colonic strictures
Arieira et al 2019	CECDAIic	Panenteric	22	Retrospective	Interobserver agreement and the correlation with inflammatory parameters.	Excellent interobserver agreement (k = 0.94) and strong correlation with calprotectin levels (r = 0.82) moderate correlation with CRP (r = 0.5)
Hosoe et al 2018	Capsule Scoring of Ulcerative Colitis (CSUC)	Large bowel	40	Prospective	Development of endoscopic score for UC with colon capsule endoscopy 2	Correlation of newly developed CSUC (score 0–14 based on with fecal calprotectin and Lichtiger index)
Macedo Silva et al 2022	APEX score	Small bowel	47	Retrospective	Prediction of flare in small bowel CD	Age ≤ 30 y (+ 3 points), platelet count ≥ 280 × 103/L (+2 points) and extraintestinal manifestations (+2 points) to calculate APEX score (low: 0–3, high: 4–7) to predict CD flare during the first year after achieving mucosal healing

Abbreviations: CD, Crohn's disease; CECDAIic, Capsule Endoscopy Crohn's Disease Activity Index; CRP, c-reactive protein; ICCE, International Conference on Capsule Endoscopy; LS, Lewis score; MRE, magnetic resonance enterography.

 

MissingLinkText

3.7.2. Capsule Endoscopy Crohn's Disease Activity Index

Capsule Endoscopy Crohn's Disease Activity Index (CECDAI) or Niv score was also developed at the same time as the LS (2008) which was simpler and based on severity of inflammation, extent of disease, and narrowing in proximal and distal small bowel. Interobserver agreement was strong (k = 0.87) in single center and good between different centers (k = 0.767).[173] [174] The score has been validated by Ponte et al in 2018 which showed that the corresponding cut-off value of CECDAI for LS between 135 and 790 was 7.7 to 10.3.[175] Another study showed the cut-off value to be 3.8 to 5.8 which also showed that LS better correlates with fecal calprotectin (<100 μg/g) than CECDAI.[176] [177] In comparison to LS, a retrospective study has shown that CECDAI may better predict intestinal inflammation. Those with high LS and normal CECDAI may reflect strictures rather than active inflammation.[58]

 

MissingLinkText

3.7.3. Panenteric Capsule Endoscopy Scores

As panenteric evaluation became feasible with VCE, panenteric scores were developed. The first one was CECDAlic which was an extension of CECDAI score into colon. Inflammation, extent of disease, and narrowing were evaluated in proximal small bowel, distal small bowel, right colon, and left colon. The concordance was high for small bowel (Kendell's coefficient: k = 0.85) and panenteric evaluation (k = 0.77) except for strictures in proximal small intestine and distal colon.[178] Later, it was validated and was shown to have excellent interobserver agreement (k = 0.94).[179]

The second panenteric score was based on novel PillCam Crohn's (PCC) (Medtronic, Dublin, Ireland) capsule. Panenteric scores were calculated from five areas: three tertiles of small intestine, right, and left colon. Each subscore was calculated using most common lesion (1), most severe lesion (2), extent of disease (3), and stricture (4) (each parameter rated from 0 to 3). Each segmental score was ([A + B] × C) +D. This score also named as the Elaikim score was shown to have an excellent correlation with LS and had excellent interobserver agreement (k = 0.9).[180]

 

MissingLinkText

3.7.4. Capsule Scoring of Ulcerative Colitis

Similar to ulcerative colitis endoscopic activity index (UCEIS), Capsule Scoring of Ulcerative Colitis (CSUC) is based on parameters like vascular pattern (0: none, patchy obliteration[1] <30%, obliterated[2] >30%), bleeding (0: none, automated suspected blood indicator <10 = 1, >10 = 2), and erosions/ulcers (0: none, 1: <5 mm erosion, 2: >5 mm superficial ulcer, 3: excavated deep ulcer ± excavation/raised margins) in second-generation colon capsule endoscopy. Each item was subdivided into proximal and distal parts with the reference point being the splenic flexure. The total score was 0 to 14. Its correlation with fecal calprotectin, CRP, and clinical Lichtiger index was similar to UCEIS.[181]

 

MissingLinkText

3.7.5 APEX Score

This is based on age (≤30 years) (+3), platelet count (≥280 × 10³/L) (+2), and extraintestinal manifestations (+2) which were shown to predict risk of 1 year relapse after achieving mucosal healing in small bowel CD based on a recent retrospective study.[182]

 

MissingLinkText

 

MissingLinkText

3.8. Interobserver Agreement in Diagnosing Small Bowel Crohn's Disease with Video Capsule Endoscopy

There is substantial interobserver agreement (IOA) for the detection of small bowel CD with VCE (k = 0.68). IOA was moderate for localization (k = 0.44) and only fair for aphthous ulcers (k = 0.38). Although small bowel CD can be diagnosed confidently with VCE, diagnosis can be observer dependent in those with few lesions. Differentiating ileal from cecal lesions can be difficult in a minority of patients.[183]

 

MissingLinkText

3.9. Artificial Intelligence

Study Selection and Study Characteristics

We found nine original articles on the use of artificial intelligence in VCE related to IBD.

 

MissingLinkText

Results

AI technology was used for Pillcam SB 3, panenteric capsule, and colon capsule. A variable number of training images (469–483,444) were used to develop the various AI technology followed by validation. The sensitivity and specificity of the AI models were 80 to 97.1% and 89 to 98.1%, respectively[184] [185] [186] [187] [188] [189] [190] [191] [192] ([Supplementary Table S4], available in the online version). Hence, AI can significantly reduce the examination time with excellent sensitivity and specificity.

 

MissingLinkText

 

MissingLinkText

3.10 Novel Techniques and Future Directions

Study Selection and Study Characteristics

We found eight original articles describing various technical advances for VCE in IBD[5] [193] [194] [195] [196] [197] [198] [199]([Table 6]).

Table 6 Summary of studies studying technological advances in video capsule endoscopy pertaining to inflammatory bowel disease

Author and year	Indication	N	Capsule technology	Basic principle	Advantages	Drawbacks
Yung et al 2021	Small bowel inflammation and reassessment of known IBD	84	MiroCam MC2000	Double head capsule instead of conventional single head capsule	13.1% clinically significant different finding with new technology	Potential to overreport if the same lesion is visualized at different time points by different camera heads
Yau et al 2021	IBD	Pre-clinical	Recoverable sampling system	Automatic sampling of gastrointestinal fluids and storage of analytes using preservatives to stabilize DNA and proteins	May enable sampling of GI fluid without endoscopy	Intact ileo-cecal valve is mandatory for triggering tissue sampling
Tontini et al 2020	Suspected or known CD	41	PillCamTM Crohn's System, PCS; Medtronic, Dublin, Ireland	344 degree panoramic view	Higher diagnostic yield (56 vs. 39%) Better clinical management (48.8 vs. 31.7%)	Overestimation of lesion Higher reading time Lower image quality
Nam et al 2020	Suspected or known CD	14	MiroCam MC4000	3D reconstruction using stereo camera-based technology	3D reconstruction Size estimation for lesions	The value in altering clinical management not clear Size estimation function needs validation
Koulaouzidis et al 2012	Suspected or known CD	81	QuickView (QV) mode RAPID capsule view software	Rapid capsule video review	Reduction in capsule reading time	Blue mode does not add any advantage over white light Decreased overall diagnostic yield
Halling et al 2013	Suspected CD	40	QV mode RAPID capsule view software	Rapid capsule video review	Reduction in capsule reading time Sensitivity 94% Diagnostic accuracy 98%	False negative in terminal ileal lesions Significant number of missed lesions
Freitas et al 2020	Suspected or known CD	115	TOP 100 software tool of the RAPID Reader	Automatic selection of 100 images that will most likely contain abnormalities	Prompt calculation of Lewis score and high agreement in moderate to severe inflammatory activity	Needs further validation Agreement less in mild inflammatory activity
Tontini et al 2014	CD	1	CapsoCam SV-1 (Capso- Vision, Inc. Saratoga, CA, United States)	Lateral panoramic 360 degree viewing	Improved diagnostic yield	Needs further validation

Abbreviations: CD, Crohn's disease; IBD, inflammatory bowel disease.

 

MissingLinkText

Results

To increase the visibility and diagnostic yield, double head capsule and 344 degree panoramic view capsules have been developed.[198] For rapid review, the QuickView mode of RAPID capsule view software can reduce the reading time with excellent diagnostic accuracy up to 98%.[194] 3D reconstruction can help in the estimation of size of lesions.[197]

A novel RSS capsule technology has been developed which may allow noninvasive sampling, preservation, and storage of analytes found in gastrointestinal fluids which can correlate with inflammation and gut permeability. The preservative contained in the novel capsule stabilizes DNA and proteins for analysis after expulsion.[5]

 

MissingLinkText

 

MissingLinkText

3.11. Cleansing Regimen

A randomized controlled trial in pediatric patients has shown that 25 mL/kg of polyethylene glycol (PEG) solution plus 20 mL (376 mg) of oral simethicone was superior to high volume PEG (50 mL/kg), oral simethicone, and low-dose PEG alone (25 mL/kg) with regard to better visualization but not diagnostic yield.[200] According to a prospective study, the addition of 15 mL of castor oil to 1 L of Moviprep and 10 mg bisacodyl significantly improved colon capsule endoscopy completion rates (87 vs. 73%) and polyp detection (82 vs. 44%)[201].

 

MissingLinkText

 

MissingLinkText

 

MissingLinkText

4. Discussion

VCE is indicated in suspected small bowel CD after negative IC (nearly 10% of small bowel CD) if there are no obstructive symptoms or known stenosis/history of bowel surgery. If these are present, cross-sectional imaging (CT/MRE) is warranted. In those with positive findings in IC, VCE may still be indicated for mapping of the disease as one-third may have proximal bowel involvement.[44] The inherent limitation of VCE to evaluate the extraluminal involvement can be an additional reason to use cross-sectional imaging upfront especially in tuberculosis endemic regions where distal small bowel involvement often leads to TB and CD dilemma. The long duration of symptoms should also be kept in mind as it may indicate stricturing complications with high risk of retention.[6] VCE is also helpful to exclude differential diagnosis like TB and diagnose CD in presymptomatic patients.

The role of VCE in known CD ranged from diagnosis of active disease (highest in symptomatic patients), change in treatment decisions (escalation or deescalation of treatment and surgical decision), reclassification of disease, assessment of mucosal healing, and prediction of relapse. The yield was noninferior to MRI. However, the risk of retention is higher in known CD. PCCE has high agnostic accuracy in detecting active disease in small and large bowels.

VCE can also be useful in postoperative settings. However, the drawbacks of VCE in postoperative settings are lower yield in neoterminal ileum, inability to perform in those with positive patency testing, and poor correlation of endoscopic activity in VCE and clinical recurrence.

Capsule endoscopy can have role in relatively noninvasive monitoring of disease activity in UC with excellent correlation with colonoscopy. It has the advantage of identifying small bowel involvement although the preparation may be poor in a third of the patients.

VCE scores have a good correlation with cross-sectional imaging (e.g., MRI scores) and can be helpful to establish the extent of small bowel, panenteric, and large bowel involvement with the existing scores (Lewis, CECDAI, Capsule Endoscopy Crohn's Disease Activity Index [CECDAIic], CSUC). Scores like APEX can predict the risk of relapse in small bowel CD.

Technical advances in the form of artificial intelligence, technical modification, and various software packages can reduce reading time with high diagnostic accuracy. Technology like RSS has the potential to guide therapy by disease monitoring and characterization and may also help in developing novel therapeutic targets.

The limitations of the review include qualitative nature and inclusion of primarily uncontrolled, noncomparative studies. The highest quality citations included good-quality prospective studies. Individual meta-analysis of the different outcomes is out of the scope of this broader systematic review. The strength of this review is the inclusion of all relevant articles pertaining to the role of VCE in IBD. The review implies the need for further comparative studies such as comparing MRI with VCE in suspected and known CD or comparison of VCE with other modalities like IC for diagnosing postoperative recurrence. In areas where randomized controlled trials are not available, high-quality prospective studies can give true estimates of VCE yield in scenarios such as IBD-U and pouchitis and their implications in future disease courses.

 

MissingLinkText

Conclusion

Capsule endoscopy is indicated in the evaluation of suspected small bowel CD irrespective of findings of IC to map small intestinal involvement, and the diagnostic yield is superior to other modalities except MRE. Hence, VCE should be the preferred investigation in suspected CD in the absence of obstructive symptoms or known stenosis. A cross-sectional imaging (CTE/MRE) or patency capsule testing should be done prior to CE in suspected stricturing CD or established CD. In known CD, VCE should not be preferred over cross-sectional imaging due to the risk of retention. It can be done in established CD to evaluate unexplained anemia, obscure GI bleed, and sometimes assessment of mucosal healing. Capsule retention is usually asymptomatic, however, symptomatic cases can be treated with balloon or spiral enteroscopy-guided retrieval failing which surgery is warranted. Various scoring systems are available for small bowel, colon, and panenteric evaluation. Scoring systems at VCE can help to determine severity and disease course similar to endoscopic scoring. VCE is useful to assess postoperative CD, IBD-U, and noninvasive monitoring of UC. Artificial intelligence and newer technologies increase the diagnostic yield and reading time of VCE and are the future avenues in this evolving field.

Supplementary Table S1 Studies evaluating risk and predictors of capsule retention and the role of patency capsule in suspected and established Crohn's disease

Author	Indication	Study type	N	Incidence rate of retention	Predictors	Outcome
Albuquerque et al 2016	Crohn's disease	Retrospective	151	28% patency capsule retention	Stricturing disease, penetrating disease, left colonic lesions, ileal stricture Previous surgery was protective for patency capsule retention	–
Atay et al 2009	Known CD, pediatric	Retrospective	58	5.2% 0% in suspected CD 43% if BMI <5th percentile 37.5% small bowel CD on SBFT	Known CD, BMI< 5th percentile, small bowel CD on SBFT	–
Cheifetz et al 2006	Suspected or known CD	Retrospective	102	1.6% suspected CD 13% known CD	Known CD Undetected stricture on SBFT	4 out of 5 underwent nonemergent surgery, one asymptomatic without surgery at 38 mo
Cohen et al 2011	Pediatric suspected and known CD, UC, indeterminate colitis	Prospective	18	3 out of 18 had patency capsule retention	Possibility of CD higher (100%) if patency capsule transit time is ≥40 hours (delayed passage) and is 75% if transit time <40 hours	No retention after patency capsule testing
Delvaux et al 2005	Suspected or known CD	Prospective	15	27.2% retention of patency capsule in small bowel	Suspected stenosis on CT/SBFT Patency capsule did not detect any new stenosis	3 patients symptomatic intestinal obstruction- 2 required emergent surgery
Fork et al 2012	Suspected CD	Prospective	20	None after patency capsule	–	–
Klang et al 2017	Known CD	Prospective	80	18.8% retained patency capsule	Restricted diffusion on diffusion-weighted MRI in the distal ileum, 100% sensitivity and negative predictive value, specificity nearly 50%	None of the capsule endoscopes were retained after negative patency capsule testing, and no adverse outcomes for retained patency capsules
Kono et al 2014	Postsurgical CD	Prospective	19	None	–	Earlier diagnosis of endoscopic recurrence
Nakano et al 2015	Suspected small bowel stricturing CD	Prospective	50	3 had pain abdomen after patency capsule, 1 had ileus, and 1 had persistent film coating	Extensive bowel wall thickening on transabdominal ultrasound is highly predictive of small bowel strictures	None required surgery, one with persistent film coating was removed with double-balloon enteroscopy
Nemeth et al 2016	Known CD	Retrospective	406	2.3% (11% after positive patency test, 2.1% after negative patency test and 1.5% without prior patency capsule test)	Positive patency capsule test, risk of retention not reduced by nonselective use of patency capsule	Symptomatic capsule retention in one patient after second patency capsule test was negative after initial positive test
Otsuka et al 2021	Suspected GI stenosis/CD	Prospective	23	4% with patency capsule, none after negative patency capsule for colon capsule endoscope	Negative patency capsule testing before colon capsule endoscopy is helpful for detecting large bowel lesions in suspected GI stenosis	No complications after negative patency capsule testing
Pasha et al, 2020	Suspected or known CD	Meta-analysis	4219	Overall CD: 3.32% Established CD: 4.63% Suspected CD: 2.35% Adult CD: 3.49% Pediatric CD: 1.64% Established CD (after patency capsule): 2.88% Established CD (after MR/CT enterography): 2.32%	Established CD Adult established CD Pediatric established and suspected CD similar retention rates Negative patency capsule test and MR/CT enterography: negative predictors	Lower retention rates after negative patency capsule testing and MR/CT enterography
Rozendorn et al 2016	Known CD	Prospective	57	28.9% (13/45) in those with active inflammation on MR enterography	Higher stricture length and number of prestenotic dilations were associated with patency capsule retention Stricturing disease phenotype also associated with patent capsule retention	No adverse events reported with patency capsule
Signorelli et al 2006	Known CD, previous surgery/obstruction	Retrospective	32	No capsule retention in those who had negative patency capsule testing	Negative patency capsule testing	2 pain abdomen, 4 nonexcretion of patency capsule
Silva et al 2019	Known CD	Prospective	54	20% patency capsule retention rate with radio frequency detector, CT showed 9% retention rate	CRP > 5 mg/dL, penetrating disease, history of abdominal surgery	4% symptomatic patency capsule retention and 2% self-resolving small bowel obstruction
Singeap et al 2011	Suspected small bowel obstruction	Retrospective	15	20%	Radiation enteritis, Crohn's disease, ileal tumor	Subacute obstruction and surgery
Spada et al 2007	Suspected or known small bowel stricture	Prospective	27	7.4%	Successful capsule endoscopy in 65.3% who excreted intact patency capsule	Occlusive symptom
Yoshimura et al 2018	Known CD	Retrospective	99	15.2% patency capsule retention rates	–	Those with negative patency capsule testing had lower surgery and hospitalization over next 2 y

Abbreviations: BMI, body mass index; CD, Crohn's disease; CRP, c-reactive protein; CT, computed tomography; GI, gastrointestinal; MRI, magnetic resonance imaging; SBFT, small bowel follow through.

Supplementary Table S2 Studies evaluating postoperative recurrence in Crohn's disease with video capsule endoscopy

	N	Type of study	Comparator	Incremental yield	Drawbacks of capsule endoscopy
Beltran et al 2007	24	Prospective	Colonoscopy	41.6% recurrence seen only on capsule endoscopy 54.2% proximal involvement detected Therapeutic management changed in 66.7% patients Patients preferred capsule endoscopy more than colonoscopy	In 8.3% (2/24) delayed excretion of patency capsule precluding capsule endoscopy
Biancone et al 2007	22	Prospective	SICUS Colonoscopy	Yield similar to colonoscopy and SICUS	Cannot be done in 5/22 (22.7%) due to luminal stenosis
Bourreille et al 2007	32	Prospective	Colonoscopy	Capsule endoscopy was superior to colonoscopy for detecting lesions beyond reach of colonoscopy	Capsule endoscopy was inferior to colonoscopy for detecting lesions in neo-terminal ileum
Han et al 2018	83	Retrospective	Colonoscopy	Detected recurrence in 29.7% (11/37) patients not identified by capsule endoscopy	–
Hausmann et al 2017	22	Prospective	Colonoscopy	After 8 weeks of surgery capsule endoscopy detected lesions in 50% (6/12) compared with 33.3% (5/15) with ileo-colonoscopy	Capsule endoscopy could not be done in 3 patients due to positive patency capsule test
Kusaka et al 2018	25	Prospective	Colonoscopy Small bowel series	84% had endoscopic activity (21/25), higher clinical recurrence in those with highest third tertile Lewis score None were detected by colonoscopy or small bowel series	Endoscopic severity index did not predict clinical recurrence
Shiga et al 2021	105	Prospective	No capsule endoscopy	Capsule endoscopy arm had lower hospitalization, surgery or balloon dilation compared with no capsule endoscopy arm due to treatment adjustments based on findings	6 patients out of 48 eligible patients could not undergo capsule endoscopy based on patency testing

Abbreviations: CD, Crohn's disease; ICCE, International Conference on Capsule Endoscopy; LS, Lewis score; SICUS, small intestinal contrast ultrasonography.

Supplementary Table S3 Summary of studies evaluating role of video capsule endoscopy in inflammatory bowel disease-unclassified

Author	N	Study type	Diagnosis of CD	False negative (CD on follow-up)	Change in treatment after CD diagnosis	Diagnosis of UC	No change in IBD-U diagnosis	Predictive factor for diagnosis of CD
Monteiro et al 2017	36	Retrospective	25%	3.7%	66.7%	59.3%	37%	LS ≥ 135 predictive of CD diagnosis (sensitivity: 90%, specificity:100%, PPV: 100%, NPV: 94%)
Maunoury et al 2007	30	Prospective	16.7%	16.7%	100%	6.6%	60%	Not evaluated
Lopes et al 2010	18	Prospective	38.9%	5.5%	0%	5.5%	50%	Not evaluated
Kalla et al 2013	37	Retrospective	38%	–	57%	–	–	–
Nardo et al 2011	26 (pediatric)	Prospective	61.5%	–	–	–	–	–
Ouahed et al 2013	10 (pediatric)	Prospective	30%	–	100%	30%	40%	–
Min et al 2013	16 (pediatric)	Retrospective	25%	–	–	–	75%	–
Granlek et al 2012	2 (pediatric)	Prospective	50%	0%	100%	50%	0%	–
Cohen et al 2011	2 (pediatric)	Retrospective	50%	0%	100%	50%	0%	–

Supplementary Table S4 Summary of studies evaluating the role of artificial intelligence in video capsule endoscopy for inflammatory bowel disease

Study	Capsule type	Technology	Lesion type	Training images	Sensitivity and specificity
Maissin et al 2021	Pillcam SB3	CrohnIPI: Multiexpert annotation using convolutional recurrent attention neural network	Erosions/ulcers/strictures	3,498	93/95
Klang et al 2021	Pillcam SB3	Deep neural networks	CD Strictures	27,892	92/89
Klang et al 2021	Pillcam SB3	Deep neural networks: Model trained on CD ulcers to identify NSAID ulcers	CD/NSAID ulcers	17,640 (CD)/ 1,605 (NSAID)	92/95
Klang et al 2020	Pillcam SB3	Deep neural networks	Known CD and control	17,640	92.5–97.1 /96–98.1
Higuchi et al 2022	PillCam COLON2	ResNet50	UC	483,644	NA Accuracy rates of training and validation sets are 0.992 and 0.973
Ferreira et al 2022	PillCam Crohn's capsule (panenteric)	Convolutional neural network	CD ulcers and erosions	8,085	90/96
Barash et al 2021	PillCam Crohn's capsule (panenteric)	Ordinal neural network solution	CD ulcers	17,640	91/91
Charisis et al 2016	Not specified	Hybrid adaptive filtering and differential lacunarity	CD ulcers	800	95.2/92.4
Kumar et al 2012	Pillcam SB	Content-based image retrieval and then statistical method to quantitatively assess the severity of inflammation	CD	469	80/93

Abbreviations: CD, Crohn's disease; NSAID, nonsteroidal anti-inflammatory drugs.

Supplementary Material S1 PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE
Title	1	Identify the report as a systematic review.	1
ABSTRACT
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	1
INTRODUCTION
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	2
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	2
METHODS
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	2
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	2
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	2
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report Retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	2
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	2
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	2
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	2
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	2
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	NA
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	2
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	2
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	2
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	NA
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	NA
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	NA
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	2
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	NA
RESULTS
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	3–19
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	2
Study characteristics	17	Cite each included study and present its characteristics.	3–19
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	3–19
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	3–19
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	3–19
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	NA
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	3,20
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	NA
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	NA
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	20
DISCUSSION
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	20
	23b	Discuss any limitations of the evidence included in the review.	20
	23c	Discuss any limitations of the review processes used.	20
	23d	Discuss implications of the results for practice, policy, and future research.	20
OTHER INFORMATION
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	NA
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.
	24c	Describe and explain any amendments to information provided at registration or in the protocol.
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.
Competing interests	26	Declare any competing interests of review authors.	NA
Availability of data, code, and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	NA

Source: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71.

For more information, visit: http://www.prisma-statement.org/

 

MissingLinkText

 

MissingLinkText

Conflict of Interest

None declared.

Authors' Contribution

P.P. was responsible for conceptualization, literature review and writing original draft, and illustrations. P.P., R.G., and P.M.R. were responsible for images. M.T., R.B., R.G., P.M.R., and D.N.R. were responsible for proof reading and critical review. M.T., P.P., R.B., R.G., P.M.R., and D.N.R. were responsible for approving final manuscript.

• References

• 1 Buisson A, Gonzalez F, Poullenot F. et al; ACCEPT study group. Comparative acceptability and perceived clinical utility of monitoring tools: a nationwide survey of patients with inflammatory bowel disease. Inflamm Bowel Dis 2017; 23 (08) 1425-1433
• 2 Goodsall TM, Noy R, Nguyen TM, Costello SP, Jairath V, Bryant RV. Systematic review: patient perceptions of monitoring tools in inflammatory bowel disease. J Can Assoc Gastroenterol 2020; 4 (02) e31-e41
• 3 Yamada K, Nakamura M, Yamamura T. et al. Diagnostic yield of colon capsule endoscopy for Crohn's disease lesions in the whole gastrointestinal tract. BMC Gastroenterol 2021; 21 (01) 75
• 4 Eliakim R, Magro F. Imaging techniques in IBD and their role in follow-up and surveillance. Nat Rev Gastroenterol Hepatol 2014; 11 (12) 722-736
• 5 Yau YY, Wasinger VC, Hirten RP. et al. Current trends in IBD-development of mucosal-based biomarkers and a novel minimally invasive recoverable sampling system. Inflamm Bowel Dis 2021; 27 (Suppl. 02) S17-S24
• 6 Pal P, Vishwakarma P, Singh AP. et al. Diagnostic yield and technical performance of the novel motorized spiral enteroscopy compared with single-balloon enteroscopy in suspected Crohn's disease: a prospective study (with video). Gastrointest Endosc 2022; (e-pub ahead of print).
• 7 Fireman Z, Mahajna E, Broide E. et al. Diagnosing small bowel Crohn's disease with wireless capsule endoscopy. Gut 2003; 52 (03) 390-392
• 8 Herrerías JM, Caunedo A, Rodríguez-Téllez M, Pellicer F, Herrerías Jr JM. Capsule endoscopy in patients with suspected Crohn's disease and negative endoscopy. Endoscopy 2003; 35 (07) 564-568
• 9 Argüelles-Arias F, Caunedo A, Romero J. et al. The value of capsule endoscopy in pediatric patients with a suspicion of Crohn's disease. Endoscopy 2004; 36 (10) 869-873
• 10 Ge ZZ, Hu YB, Xiao SD. Capsule endoscopy in diagnosis of small bowel Crohn's disease. World J Gastroenterol 2004; 10 (09) 1349-1352
• 11 Mow WS, Lo SK, Targan SR. et al. Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease. Clin Gastroenterol Hepatol 2004; 2 (01) 31-40
• 12 De Bona M, Bellumat A, Cian E, Valiante F, Moschini A, De Boni M. Capsule endoscopy findings in patients with suspected Crohn's disease and biochemical markers of inflammation. Dig Liver Dis 2006; 38 (05) 331-335
• 13 van Tuyl SA, Van Noorden JT, Kuipers EJ, Stolk MF. Results of videocapsule endoscopy in 250 patients with suspected small bowel pathology. Dig Dis Sci 2006; 51 (05) 900-905
• 14 Girelli CM, Porta P, Malacrida V, Barzaghi F, Rocca F. Clinical outcome of patients examined by capsule endoscopy for suspected small bowel Crohn's disease. Dig Liver Dis 2007; 39 (02) 148-154
• 15 May A, Manner H, Schneider M, Ipsen A, Ell C. Prospective multicenter trial of capsule endoscopy in patients with chronic abdominal pain, diarrhea and other signs and symptoms (CEDAP-Plus Study). Endoscopy 2007; 39 (07) 606-612
• 16 van Tuyl SA, van Noorden JT, Stolk MF, Kuipers EJ. Clinical consequences of videocapsule endoscopy in GI bleeding and Crohn's disease. Gastrointest Endosc 2007; 66 (06) 1164-1170
• 17 Moy L, Levine J. Capsule endoscopy in the evaluation of patients with unexplained growth failure. J Pediatr Gastroenterol Nutr 2009; 48 (05) 647-650
• 18 Tukey M, Pleskow D, Legnani P, Cheifetz AS, Moss AC. The utility of capsule endoscopy in patients with suspected Crohn's disease. Am J Gastroenterol 2009; 104 (11) 2734-2739
• 19 Figueiredo P, Almeida N, Lopes S, Duque G, Freire P, Lérias C. et al. Small-bowel capsule endoscopy in patients with suspected Crohn's disease-diagnostic value and complications. Diagn Ther Endosc 2010; (e-pub ahead of print).
• 20 Nuutinen H, Kolho KL, Salminen P. et al. Capsule endoscopy in pediatric patients: technique and results in our first 100 consecutive children. Scand J Gastroenterol 2011; 46 (09) 1138-1143
• 21 Adler SN, Yoav M, Eitan S, Yehuda C, Eliakim R. Does capsule endoscopy have an added value in patients with perianal disease and a negative work up for Crohn's disease?. World J Gastrointest Endosc 2012; 4 (05) 185-188
• 22 Cohen SA, Ephrath H, Lewis JD. et al. Pediatric capsule endoscopy: review of the small bowel and patency capsules. J Pediatr Gastroenterol Nutr 2012; 54 (03) 409-413
• 23 Gralnek IM, Cohen SA, Ephrath H. et al. Small bowel capsule endoscopy impacts diagnosis and management of pediatric inflammatory bowel disease: a prospective study. Dig Dis Sci 2012; 57 (02) 465-471
• 24 Kalla R, McAlindon ME, Drew K, Sidhu R. Clinical utility of capsule endoscopy in patients with Crohn's disease and inflammatory bowel disease unclassified. Eur J Gastroenterol Hepatol 2013; 25 (06) 706-713
• 25 Min SB, Le-Carlson M, Singh N. et al. Video capsule endoscopy impacts decision making in pediatric IBD: a single tertiary care center experience. Inflamm Bowel Dis 2013; 19 (10) 2139-2145
• 26 Esaki M, Matsumoto T, Watanabe K. et al. Use of capsule endoscopy in patients with Crohn's disease in Japan: a multicenter survey. J Gastroenterol Hepatol 2014; 29 (01) 96-101
• 27 Egnatios J, Kaushal K, Kalmaz D, Zarrinpar A. Video capsule endoscopy in patients with chronic abdominal pain with or without associated symptoms: a retrospective study. PLoS One 2015; 10 (04) e0126509
• 28 Lee HS, Lim YJ. Capsule endoscopy for ileitis with potential involvement of other sections of the small bowel. Gastroenterol Res Pract 2016; 2016: 9804783
• 29 Mitselos IV, Christodoulou DK, Katsanos KH. et al. The role of small bowel capsule endoscopy and ileocolonoscopy in patients with nonspecific but suggestive symptoms of Crohn's disease. Eur J Gastroenterol Hepatol 2016; 28 (08) 882-889
• 30 Song HJ, Moon JS, Jeon SR. et al; Korean Gut Image Study Group. Diagnostic yield and clinical impact of video capsule endoscopy in patients with chronic diarrhea: A Korean Multicenter CAPENTRY Study. Gut Liver 2017; 11 (02) 253-260
• 31 Eliakim R, Spada C, Lapidus A. et al. Evaluation of a new pan-enteric video capsule endoscopy system in patients with suspected or established inflammatory bowel disease—feasibility study. Endosc Int Open 2018; 6 (10) E1235-E1246
• 32 Huang L, Huang Z, Tai Y, Wang P, Hu B, Tang C. The small bowel diseases detected by capsule endoscopy in patients with chronic abdominal pain: a retrospective study. Medicine (Baltimore) 2018; 97 (08) e0025
• 33 de Sousa Magalhães R, Rosa B, Marques M. et al. How should we select suspected Crohn's disease patients for capsule enteroscopy?. Scand J Gastroenterol 2019; 54 (08) 991-997
• 34 Wu J, Huang Z, Wang Y. et al. Clinical features of capsule endoscopy in 825 children: a single-center, retrospective cohort study. Medicine (Baltimore) 2020; 99 (43) e22864
• 35 Tai FWD, Ellul P, Elosua A. et al. Panenteric capsule endoscopy identifies proximal small bowel disease guiding upstaging and treatment intensification in Crohn's disease: a European multicentre observational cohort study. United European Gastroenterol J 2021; 9 (02) 248-255
• 36 Brodersen JB, Andersen KW, Jensen MD. Adherence to the bowel cleansing regimen for pan-enteric capsule endoscopy in patients with suspected Crohn's disease and factors affecting the image quality. Scand J Gastroenterol 2022; 57 (04) 501-506
• 37 Elosua González A, Nantes Castillejo Ó, Fernández-Urién Sainz I, López-García A, Murcia Pomares Ó, Zabana Y. en nombre de Grupo Joven GETECCU y del Grupo Joven de AEG. Use of capsule endoscopy in inflammatory bowel disease in clinical practice in Spain. Results from a national survey. Gastroenterol Hepatol 2021; 44 (10) 696-703
• 38 Dionisio PM, Gurudu SR, Leighton JA. et al. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn's disease: a meta-analysis. Am J Gastroenterol 2010; 105 (06) 1240-1248 , quiz 1249
• 39 Choi M, Lim S, Choi MG, Shim KN, Lee SH. Effectiveness of capsule endoscopy compared with other diagnostic modalities in patients with small bowel Crohn's disease: a meta-analysis. Gut Liver 2017; 11 (01) 62-72
• 40 Sihag S, Tan B, Semenov S. et al. Development of significant disease in a cohort of patients with non-specific enteritis on capsule endoscopy: clinical suspicion and a high base line Lewis score are predictive of Crohn's disease. BMC Gastroenterol 2020; 20 (01) 341
• 41 Rana SS, Sharma V, Sharma R, Nada R, Gupta R, Bhasin DK. Capsule endoscopy in small bowel Crohn's disease and tuberculosis. Trop Doct 2017; 47 (02) 113-118
• 42 Fidder HH, Nadler M, Lahat A. et al. The utility of capsule endoscopy in the diagnosis of Crohn's disease based on patient's symptoms. J Clin Gastroenterol 2007; 41 (04) 384-387
• 43 Xue M, Chen X, Shi L, Si J, Wang L, Chen S. Small-bowel capsule endoscopy in patients with unexplained chronic abdominal pain: a systematic review. Gastrointest Endosc 2015; 81 (01) 186-193
• 44 Rodrigues-Pinto E, Cardoso H, Rosa B. et al. Development of a predictive model of Crohn's disease proximal small bowel involvement in capsule endoscopy evaluation. Endosc Int Open 2016; 4 (06) E631-E636
• 45 Valle J, Alcántara M, Pérez-Grueso MJ. et al. Clinical features of patients with negative results from traditional diagnostic work-up and Crohn's disease findings from capsule endoscopy. J Clin Gastroenterol 2006; 40 (08) 692-696
• 46 Hale MF, Drew K, McAlindon ME, Sidhu R. The diagnostic accuracy of faecal calprotectin and small bowel capsule endoscopy and their correlation in suspected isolated small bowel Crohn's disease. Eur J Gastroenterol Hepatol 2016; 28 (10) 1145-1150
• 47 Aggarwal V, Day AS, Connor S. et al. Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse. Gastrointest Endosc 2017; 86 (06) 1070-1078
• 48 Sipponen T, Haapamäki J, Savilahti E. et al. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. Scand J Gastroenterol 2012; 47 (07) 778-784
• 49 Yang L, Ge ZZ, Gao YJ. et al. Assessment of capsule endoscopy scoring index, clinical disease activity, and C-reactive protein in small bowel Crohn's disease. J Gastroenterol Hepatol 2013; 28 (05) 829-833
• 50 Höög CM, Bark LÅ, Broström O, Sjöqvist U. Capsule endoscopic findings correlate with fecal calprotectin and C-reactive protein in patients with suspected small-bowel Crohn's disease. Scand J Gastroenterol 2014; 49 (09) 1084-1090
• 51 Egea Valenzuela J, Pereñíguez López A, Pérez Fernández V, Alberca de Las Parras F, Carballo Álvarez F. Fecal calprotectin and C-reactive protein are associated with positive findings in capsule endoscopy in suspected small bowel Crohn's disease. Rev Esp Enferm Dig 2016; 108 (07) 394-400
• 52 Kopylov U, Yung DE, Engel T. et al. Fecal calprotectin for the prediction of small-bowel Crohn's disease by capsule endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2016; 28 (10) 1137-1144
• 53 Koulaouzidis A, Sipponen T, Nemeth A. et al. Association between fecal calprotectin levels and small-bowel inflammation score in capsule endoscopy: a multicenter retrospective study. Dig Dis Sci 2016; 61 (07) 2033-2040
• 54 Bar-Gil Shitrit A, Koslowsky B, Livovsky DM. et al. A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy. Scand J Gastroenterol 2017; 52 (03) 328-333
• 55 Mitselos IV, Katsanos KH, Tatsioni A. et al. Association of clinical and inflammatory markers with small bowel capsule endoscopy findings in Crohn's disease. Eur J Gastroenterol Hepatol 2018; 30 (08) 861-867
• 56 Monteiro S, Barbosa M, Cúrdia Gonçalves T. et al. Fecal calprotectin as a selection tool for small bowel capsule endoscopy in suspected Crohn's disease. Inflamm Bowel Dis 2018; 24 (09) 2033-2038
• 57 Yousuf H, Aleem U, Egan R, Maheshwari P, Mohamad J, McNamara D. Elevated faecal calprotectin levels are a reliable non-invasive screening tool for small bowel Crohn's disease in patients undergoing capsule endoscopy. Dig Dis 2018; 36 (03) 202-208
• 58 Omori T, Kambayashi H, Murasugi S. et al. Comparison of Lewis Score and Capsule Endoscopy Crohn's Disease Activity Index in patients with Crohn's Disease. Dig Dis Sci 2020; 65 (04) 1180-1188
• 59 Jung ES, Lee SP, Kae SH, Kim JH, Kim HS, Jang HJ. Diagnostic accuracy of fecal calprotectin for the detection of small bowel Crohn's disease through capsule endoscopy: an updated meta-analysis and systematic review. Gut Liver 2021; 15 (05) 732-741
• 60 Xiang B, Dong Z, Dai C. The diagnostic and predictive value of fecal calprotectin and capsule endoscopy for small-bowel Crohn's disease: a systematic review and meta-analysis. Rev Esp Enferm Dig 2021; 113 (03) 193-201
• 61 Egea-Valenzuela J, González Suárez B, Sierra Bernal C. et al. Development and validation of a scoring index to predict the presence of lesions in capsule endoscopy in patients with suspected Crohn's disease of the small bowel: a Spanish multicenter study. Eur J Gastroenterol Hepatol 2018; 30 (05) 499-505
• 62 Rosa B, Moreira MJ, Rebelo A, Cotter J. Lewis Score: a useful clinical tool for patients with suspected Crohn's Disease submitted to capsule endoscopy. J Crohn's Colitis 2012; 6 (06) 692-697
• 63 Robertson AR, Yung DE, Arnott ID, Plevris JN, Koulaouzidis A. Capsule endoscopy in suspected small bowel Crohn's disease—is it worth repeating a negative study?. Dig Liver Dis 2019; 51 (01) 174-176
• 64 Teshima CW, Goodman KJ, El-Kalla M. et al. Increased intestinal permeability in relatives of patients with Crohn's disease is not associated with small bowel ulcerations. Clin Gastroenterol Hepatol 2017; 15 (09) 1413-1418.e1
• 65 Taylor KM, Hanscombe KB, Prescott NJ. et al. Genetic and inflammatory biomarkers classify small intestine inflammation in asymptomatic first-degree relatives of patients with Crohn's disease. Clin Gastroenterol Hepatol 2020; 18 (04) 908-916.e13
• 66 Eliakim R, Karban A, Markovits D. et al. Comparison of capsule endoscopy with ileocolonoscopy for detecting small-bowel lesions in patients with seronegative spondyloarthropathies. Endoscopy 2005; 37 (12) 1165-1169
• 67 Gheorghe A, Zahiu DCM, Voiosu TA, Mateescu BR, Voiosu MR, Rimbaş M. Is the use of AGILE patency capsule prior to videocapsule endoscopy useful in all patients with spondyloarthritis?. Rom J Intern Med 2017; 55 (02) 82-88
• 68 Kopylov U, Starr M, Watts C, Dionne S, Girardin M, Seidman EG. Detection of Crohn disease in patients with spondyloarthropathy: the SpACE capsule study. J Rheumatol 2018; 45 (04) 498-505
• 69 Taddio A, Simonini G, Lionetti P. et al. Usefulness of wireless capsule endoscopy for detecting inflammatory bowel disease in children presenting with arthropathy. Eur J Pediatr 2011; 170 (10) 1343-1347
• 70 Park CH, Kim JO, Choi MG. et al. Utility of capsule endoscopy for the classification of Crohn's disease: a multicenter study in Korea. Dig Dis Sci 2007; 52 (06) 1405-1409
• 71 Cohen SA, Gralnek IM, Ephrath H. et al. Capsule endoscopy may reclassify pediatric inflammatory bowel disease: a historical analysis. J Pediatr Gastroenterol Nutr 2008; 47 (01) 31-36
• 72 Lorenzo-Zúñiga V, de Vega VM, Domènech E, Cabré E, Mañosa M, Boix J. Impact of capsule endoscopy findings in the management of Crohn's Disease. Dig Dis Sci 2010; 55 (02) 411-414
• 73 Mehdizadeh S, Chen GC, Barkodar L. et al. Capsule endoscopy in patients with Crohn's disease: diagnostic yield and safety. Gastrointest Endosc 2010; 71 (01) 121-127
• 74 Petruzziello C, Onali S, Calabrese E. et al. Wireless capsule endoscopy and proximal small bowel lesions in Crohn's disease. World J Gastroenterol 2010; 16 (26) 3299-3304
• 75 Di Nardo G, Oliva S, Ferrari F. et al. Usefulness of wireless capsule endoscopy in paediatric inflammatory bowel disease. Dig Liver Dis 2011; 43 (03) 220-224
• 76 Long MD, Barnes E, Isaacs K, Morgan D, Herfarth HH. Impact of capsule endoscopy on management of inflammatory bowel disease: a single tertiary care center experience. Inflamm Bowel Dis 2011; 17 (09) 1855-1862
• 77 Dussault C, Gower-Rousseau C, Salleron J. et al. Small bowel capsule endoscopy for management of Crohn's disease: a retrospective tertiary care centre experience. Dig Liver Dis 2013; 45 (07) 558-561
• 78 Flamant M, Trang C, Maillard O. et al. The prevalence and outcome of jejunal lesions visualized by small bowel capsule endoscopy in Crohn's disease. Inflamm Bowel Dis 2013; 19 (07) 1390-1396
• 79 Cotter J, Dias de Castro F, Moreira MJ, Rosa B. Tailoring Crohn's disease treatment: the impact of small bowel capsule endoscopy. J Crohn's Colitis 2014; 8 (12) 1610-1615
• 80 Niv E, Fishman S, Kachman H, Arnon R, Dotan I. Sequential capsule endoscopy of the small bowel for follow-up of patients with known Crohn's disease. J Crohn's Colitis 2014; 8 (12) 1616-1623
• 81 Kopylov U, Ben-Horin S, Seidman EG, Eliakim R. Video capsule endoscopy of the small bowel for monitoring of Crohn's disease. Inflamm Bowel Dis 2015; 21 (11) 2726-2735
• 82 Kopylov U, Yablecovitch D, Lahat A. et al. Detection of small bowel mucosal healing and deep remission in patients with known small bowel Crohn's disease using biomarkers, capsule endoscopy, and imaging. Am J Gastroenterol 2015; 110 (09) 1316-1323
• 83 Santos-Antunes J, Cardoso H, Lopes S, Marques M, Nunes AC, Macedo G. Capsule enteroscopy is useful for the therapeutic management of Crohn's disease. World J Gastroenterol 2015; 21 (44) 12660-12666
• 84 Greener T, Klang E, Yablecovitch D. et al; Israeli IBD Research Nucleus (IIRN). The impact of magnetic resonance enterography and capsule endoscopy on the re-classification of disease in patients with known Crohn's disease: a prospective Israeli IBD Research Nucleus (IIRN) Study. J Crohn's Colitis 2016; 10 (05) 525-531
• 85 Hansel SL, McCurdy JD, Barlow JM. et al. Clinical benefit of capsule endoscopy in Crohn's disease: impact on patient management and prevalence of proximal small bowel involvement. Inflamm Bowel Dis 2018; 24 (07) 1582-1588
• 86 Melmed GY, Dubinsky MC, Rubin DT. et al. Utility of video capsule endoscopy for longitudinal monitoring of Crohn's disease activity in the small bowel: a prospective study. Gastrointest Endosc 2018; 88 (06) 947-955.e2
• 87 Oliva S, Aloi M, Viola F. et al. A treat to target strategy using panenteric capsule endoscopy in pediatric patients with Crohn's disease. Clin Gastroenterol Hepatol 2019; 17 (10) 2060-2067.e1
• 88 Elosua A, Rullan M, Rubio S. et al. Does capsule endoscopy impact clinical management in established Crohn's disease?. Dig Liver Dis 2022; 54 (01) 118-124
• 89 Tsibouris P, Periklis A, Chrissostomos K. et al. When Crohn's disease is in remission, more patients complete capsule endoscopy study but less lesions are identified. Saudi J Gastroenterol 2013; 19 (02) 63-68
• 90 Hall BJ, Holleran GE, Smith SM, Mahmud N, McNamara DA. A prospective 12-week mucosal healing assessment of small bowel Crohn's disease as detected by capsule endoscopy. Eur J Gastroenterol Hepatol 2014; 26 (11) 1253-1259
• 91 Hall B, Holleran G, Chin JL. et al. A prospective 52 week mucosal healing assessment of small bowel Crohn's disease as detected by capsule endoscopy. J Crohn's Colitis 2014; 8 (12) 1601-1609
• 92 Eliakim R, Fischer D, Suissa A. et al. Wireless capsule video endoscopy is a superior diagnostic tool in comparison to barium follow-through and computerized tomography in patients with suspected Crohn's disease. Eur J Gastroenterol Hepatol 2003; 15 (04) 363-367
• 93 Eliakim R, Suissa A, Yassin K, Katz D, Fischer D. Wireless capsule video endoscopy compared to barium follow-through and computerised tomography in patients with suspected Crohn's disease—final report. Dig Liver Dis 2004; 36 (08) 519-522
• 94 Hara AK, Leighton JA, Heigh RI. et al. Crohn disease of the small bowel: preliminary comparison among CT enterography, capsule endoscopy, small-bowel follow-through, and ileoscopy. Radiology 2006; 238 (01) 128-134
• 95 Casciani E, Masselli G, Di Nardo G. et al. MR enterography versus capsule endoscopy in paediatric patients with suspected Crohn's disease. Eur Radiol 2011; 21 (04) 823-831
• 96 Petruzziello C, Calabrese E, Onali S. et al. Small bowel capsule endoscopy vs conventional techniques in patients with symptoms highly compatible with Crohn's disease. J Crohn's Colitis 2011; 5 (02) 139-147
• 97 Leighton JA, Gralnek IM, Cohen SA. et al. Capsule endoscopy is superior to small-bowel follow-through and equivalent to ileocolonoscopy in suspected Crohn's disease. Clin Gastroenterol Hepatol 2014; 12 (04) 609-615
• 98 Carter D, Katz LH, Bardan E. et al. The accuracy of intestinal ultrasound compared with small bowel capsule endoscopy in assessment of suspected Crohn's disease in patients with negative ileocolonoscopy. Therap Adv Gastroenterol 2018; 11: 1756284818765908
• 99 Marmo R, Rotondano G, Piscopo R. et al. Capsule endoscopy versus enteroclysis in the detection of small-bowel involvement in Crohn's disease: a prospective trial. Clin Gastroenterol Hepatol 2005; 3 (08) 772-776
• 100 Voderholzer WA, Beinhoelzl J, Rogalla P. et al. Small bowel involvement in Crohn's disease: a prospective comparison of wireless capsule endoscopy and computed tomography enteroclysis. Gut 2005; 54 (03) 369-373
• 101 D'Haens G, Löwenberg M, Samaan MA. et al. Safety and feasibility of using the Second-Generation Pillcam Colon Capsule to assess active colonic Crohn's disease. Clin Gastroenterol Hepatol 2015; 13 (08) 1480-6.e3
• 102 Oliva S, Cucchiara S, Civitelli F. et al. Colon capsule endoscopy compared with other modalities in the evaluation of pediatric Crohn's disease of the small bowel and colon. Gastrointest Endosc 2016; 83 (05) 975-983
• 103 Leighton JA, Helper DJ, Gralnek IM. et al. Comparing diagnostic yield of a novel pan-enteric video capsule endoscope with ileocolonoscopy in patients with active Crohn's disease: a feasibility study. Gastrointest Endosc 2017; 85 (01) 196-205.e1
• 104 Ben-Horin S, Lahat A, Amitai MM. et al; Israeli IBD Research Nucleus (IIRN). Assessment of small bowel mucosal healing by video capsule endoscopy for the prediction of short-term and long-term risk of Crohn's disease flare: a prospective cohort study. Lancet Gastroenterol Hepatol 2019; 4 (07) 519-528
• 105 Hijaz NM, Attard TM, Colombo JM, Mardis NJ, Friesen CA. Comparison of the use of wireless capsule endoscopy with magnetic resonance enterography in children with inflammatory bowel disease. World J Gastroenterol 2019; 25 (28) 3808-3822
• 106 Bruining DH, Oliva S, Fleisher MR, Fischer M, Fletcher JG. BLINK study group. Panenteric capsule endoscopy versus ileocolonoscopy plus magnetic resonance enterography in Crohn's disease: a multicentre, prospective study. BMJ Open Gastroenterol 2020; 7 (01) e000365
• 107 Papalia I, Tjandra D, Quah S. et al. Colon capsule endoscopy in the assessment of mucosal healing in Crohn's disease. Inflamm Bowel Dis 2021; 27 (Supplement_2): S25-S32
• 108 Albert JG, Martiny F, Krummenerl A. et al. Diagnosis of small bowel Crohn's disease: a prospective comparison of capsule endoscopy with magnetic resonance imaging and fluoroscopic enteroclysis. Gut 2005; 54 (12) 1721-1727
• 109 Chong AK, Taylor A, Miller A, Hennessy O, Connell W, Desmond P. Capsule endoscopy vs. push enteroscopy and enteroclysis in suspected small-bowel Crohn's disease. Gastrointest Endosc 2005; 61 (02) 255-261
• 110 Dubcenco E, Jeejeebhoy KN, Petroniene R. et al. Capsule endoscopy findings in patients with established and suspected small-bowel Crohn's disease: correlation with radiologic, endoscopic, and histologic findings. Gastrointest Endosc 2005; 62 (04) 538-544
• 111 Efthymiou A, Viazis N, Mantzaris G. et al. Does clinical response correlate with mucosal healing in patients with Crohn's disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy. Inflamm Bowel Dis 2008; 14 (11) 1542-1547
• 112 Solem CA, Loftus Jr EV, Fletcher JG. et al. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc 2008; 68 (02) 255-266
• 113 Böcker U, Dinter D, Litterer C. et al. Comparison of magnetic resonance imaging and video capsule enteroscopy in diagnosing small-bowel pathology: localization-dependent diagnostic yield. Scand J Gastroenterol 2010; 45 (04) 490-500
• 114 Jensen MD, Nathan T, Rafaelsen SR, Kjeldsen J. Diagnostic accuracy of capsule endoscopy for small bowel Crohn's disease is superior to that of MR enterography or CT enterography. Clin Gastroenterol Hepatol 2011; 9 (02) 124-129
• 115 Wiarda BM, Mensink PB, Heine DG. et al. Small bowel Crohn's disease: MR enteroclysis and capsule endoscopy compared to balloon-assisted enteroscopy. Abdom Imaging 2012; 37 (03) 397-403
• 116 Kovanlikaya A, Watson E, Hayward J. et al. Magnetic resonance enterography and wireless capsule endoscopy in the evaluation of patients with inflammatory bowel disease. Clin Imaging 2013; 37 (01) 77-82
• 117 Aloi M, Di Nardo G, Romano G. et al. Magnetic resonance enterography, small-intestine contrast US, and capsule endoscopy to evaluate the small bowel in pediatric Crohn's disease: a prospective, blinded, comparison study. Gastrointest Endosc 2015; 81 (02) 420-427
• 118 González-Suárez B, Rodriguez S, Ricart E. et al. Comparison of capsule endoscopy and magnetic resonance enterography for the assessment of small bowel lesions in Crohn's disease. Inflamm Bowel Dis 2018; 24 (04) 775-780
• 119 Cheifetz AS, Kornbluth AA, Legnani P. et al. The risk of retention of the capsule endoscope in patients with known or suspected Crohn's disease. Am J Gastroenterol 2006; 101 (10) 2218-2222
• 120 Pasha SF, Pennazio M, Rondonotti E. et al. Capsule retention in Crohn's disease: a meta-analysis. Inflamm Bowel Dis 2020; 26 (01) 33-42
• 121 Albuquerque A, Cardoso H, Marques M. et al. Predictive factors of small bowel patency in Crohn's disease patients. Rev Esp Enferm Dig 2016; 108 (02) 65-70
• 122 Rozendorn N, Klang E, Lahat A. et al. Prediction of patency capsule retention in known Crohn's disease patients by using magnetic resonance imaging. Gastrointest Endosc 2016; 83 (01) 182-187
• 123 Nemeth A, Kopylov U, Koulaouzidis A. et al. Use of patency capsule in patients with established Crohn's disease. Endoscopy 2016; 48 (04) 373-379
• 124 Delvaux M, Ben Soussan E, Laurent V, Lerebours E, Gay G. Clinical evaluation of the use of the M2A patency capsule system before a capsule endoscopy procedure, in patients with known or suspected intestinal stenosis. Endoscopy 2005; 37 (09) 801-807
• 125 Signorelli C, Rondonotti E, Villa F. et al. Use of the given patency system for the screening of patients at high risk for capsule retention. Dig Liver Dis 2006; 38 (05) 326-330
• 126 Spada C, Shah SK, Riccioni ME. et al. Video capsule endoscopy in patients with known or suspected small bowel stricture previously tested with the dissolving patency capsule. J Clin Gastroenterol 2007; 41 (06) 576-582
• 127 Atay O, Mahajan L, Kay M, Mohr F, Kaplan B, Wyllie R. Risk of capsule endoscope retention in pediatric patients: a large single-center experience and review of the literature. J Pediatr Gastroenterol Nutr 2009; 49 (02) 196-201
• 128 Cohen SA, Gralnek IM, Ephrath H, Stallworth A, Wakhisi T. The use of a patency capsule in pediatric Crohn's disease: a prospective evaluation. Dig Dis Sci 2011; 56 (03) 860-865
• 129 Singeap AM, Trifan A, Cojocariu C, Sfarti C, Stanciu C. Outcomes after symptomatic capsule retention in suspected small bowel obstruction. Eur J Gastroenterol Hepatol 2011; 23 (10) 886-890
• 130 Fork FT, Karlsson N, Kadhem S, Ohlsson B. Small bowel enteroclysis with magnetic resonance imaging and computed tomography in patients with failed and uncertain passage of a patency capsule. BMC Med Imaging 2012; 12: 3
• 131 Kono T, Hida N, Nogami K. et al. Prospective postsurgical capsule endoscopy in patients with Crohn's disease. World J Gastrointest Endosc 2014; 6 (03) 88-98
• 132 Nakano M, Oka S, Tanaka S. et al. Clinical usefulness of transabdominal ultrasonography prior to patency capsule for suspected small-bowel strictures. Scand J Gastroenterol 2016; 51 (03) 281-287
• 133 Klang E, Kopylov U, Ben-Horin S. et al. Assessment of patency capsule retention using MR diffusion-weighted imaging. Eur Radiol 2017; 27 (12) 4979-4985
• 134 Yoshimura T, Hirooka Y, Nakamura M. et al. Clinical significance of gastrointestinal patency evaluation by using patency capsule in Crohn's disease. Nagoya J Med Sci 2018; 80 (01) 121-128
• 135 Silva M, Cardoso H, Cunha R. et al. Evaluation of small-bowel patency in Crohn's disease: prospective study with a patency capsule and computed tomography. GE Port J Gastroenterol 2019; 26 (06) 396-403
• 136 Otsuka H, Nakamura M, Yamamura T. et al. Feasibility of patency capsule and colon capsule endoscopy in patients with suspected gastrointestinal stenosis: a prospective study. Nagoya J Med Sci 2021; 83 (03) 419-430
• 137 Makipour K, Modiri AN, Ehrlich A. et al. Double balloon enteroscopy: effective and minimally invasive method for removal of retained video capsules. Dig Endosc 2014; 26 (05) 646-649
• 138 Mitsui K, Fujimori S, Tanaka S. et al. Retrieval of retained capsule endoscopy at small bowel stricture by double-balloon endoscopy significantly decreases surgical treatment. J Clin Gastroenterol 2016; 50 (02) 141-146
• 139 Inavolu P, Singh AP, Kanakagiri H, Reddy DN, Ramchandani M. Motorized spiral enteroscope-assisted retrieval of video capsule in a patient with Crohn's disease. VideoGIE 2020; 5 (10) 488-491
• 140 Wang YC, Pan J, Liu YW. et al. Adverse events of video capsule endoscopy over the past two decades: a systematic review and proportion meta-analysis. BMC Gastroenterol 2020; 20 (01) 364
• 141 Han ZM, Qiao WG, Ai XY. et al. Impact of capsule endoscopy on prevention of postoperative recurrence of Crohn's disease. Gastrointest Endosc 2018; 87 (06) 1489-1498
• 142 Bourreille A, Jarry M, D'Halluin PN. et al. Wireless capsule endoscopy versus ileocolonoscopy for the diagnosis of postoperative recurrence of Crohn's disease: a prospective study. Gut 2006; 55 (07) 978-983
• 143 Biancone L, Calabrese E, Petruzziello C. et al. Wireless capsule endoscopy and small intestine contrast ultrasonography in recurrence of Crohn's disease. Inflamm Bowel Dis 2007; 13 (10) 1256-1265
• 144 Pons Beltrán V, Nos P, Bastida G. et al. Evaluation of postsurgical recurrence in Crohn's disease: a new indication for capsule endoscopy?. Gastrointest Endosc 2007; 66 (03) 533-540
• 145 Hausmann J, Schmelz R, Walldorf J, Filmann N, Zeuzem S, Albert JG. Pan-intestinal capsule endoscopy in patients with postoperative Crohn's disease: a pilot study. Scand J Gastroenterol 2017; 52 (08) 840-845
• 146 Kusaka J, Shiga H, Kuroha M. et al. Residual lesions on capsule endoscopy is associated with postoperative clinical recurrence in patients with Crohn's disease. Dig Dis Sci 2018; 63 (03) 768-774
• 147 Shiga H, Abe I, Kusaka J. et al. Capsule endoscopy is useful for postoperative tight control management in patients with Crohn's disease. Dig Dis Sci 2022; 67 (01) 263-272
• 148 Cohen SA, Klevens AI. Use of capsule endoscopy in diagnosis and management of pediatric patients, based on meta-analysis. Clin Gastroenterol Hepatol 2011; 9 (06) 490-496
• 149 Higurashi T, Endo H, Yoneda M. et al. Capsule-endoscopic findings of ulcerative colitis patients. Digestion 2011; 84 (04) 306-314
• 150 Hisabe T, Ninomiya K, Matsui T. et al. Small bowel lesions detected with wireless capsule endoscopy in patients with active ulcerative colitis and with post-proctocolectomy. Dig Endosc 2011; 23 (04) 302-309
• 151 Sung J, Ho KY, Chiu HM, Ching J, Travis S, Peled R. The use of Pillcam Colon in assessing mucosal inflammation in ulcerative colitis: a multicenter study. Endoscopy 2012; 44 (08) 754-758
• 152 Hosoe N, Matsuoka K, Naganuma M. et al. Applicability of second-generation colon capsule endoscope to ulcerative colitis: a clinical feasibility study. J Gastroenterol Hepatol 2013; 28 (07) 1174-1179
• 153 Meister T, Heinzow HS, Domagk D. et al. Colon capsule endoscopy versus standard colonoscopy in assessing disease activity of ulcerative colitis: a prospective trial. Tech Coloproctol 2013; 17 (06) 641-646
• 154 Ye CA, Gao YJ, Ge ZZ. et al. PillCam colon capsule endoscopy versus conventional colonoscopy for the detection of severity and extent of ulcerative colitis. J Dig Dis 2013; 14 (03) 117-124
• 155 Oliva S, Di Nardo G, Hassan C. et al. Second-generation colon capsule endoscopy vs. colonoscopy in pediatric ulcerative colitis: a pilot study. Endoscopy 2014; 46 (06) 485-492
• 156 San Juan-Acosta M, Caunedo-Álvarez A, Argüelles-Arias F. et al. Colon capsule endoscopy is a safe and useful tool to assess disease parameters in patients with ulcerative colitis. Eur J Gastroenterol Hepatol 2014; 26 (08) 894-901
• 157 Shi HY, Chan FKL, Higashimori A. et al. A prospective study on second-generation colon capsule endoscopy to detect mucosal lesions and disease activity in ulcerative colitis (with video). Gastrointest Endosc 2017; 86 (06) 1139-1146.e6
• 158 Okabayashi S, Kobayashi T, Nakano M. et al. A simple 1-day colon capsule endoscopy procedure demonstrated to be a highly acceptable monitoring tool for ulcerative colitis. Inflamm Bowel Dis 2018; 24 (11) 2404-2412
• 159 Matsubayashi M, Kobayashi T, Okabayashi S. et al. Determining the usefulness of Capsule Scoring Of Ulcerative Colitis in predicting relapse of inactive ulcerative colitis. J Gastroenterol Hepatol 2021; 36 (04) 943-950
• 160 Calabrese C, Fabbri A, Gionchetti P. et al. Controlled study using wireless capsule endoscopy for the evaluation of the small intestine in chronic refractory pouchitis. Aliment Pharmacol Ther 2007; 25 (11) 1311-1316
• 161 Maunoury V, Savoye G, Bourreille A. et al. Value of wireless capsule endoscopy in patients with indeterminate colitis (inflammatory bowel disease type unclassified). Inflamm Bowel Dis 2007; 13 (02) 152-155
• 162 Lopes S, Figueiredo P, Portela F. et al. Capsule endoscopy in inflammatory bowel disease type unclassified and indeterminate colitis serologically negative. Inflamm Bowel Dis 2010; 16 (10) 1663-1668
• 163 Ouahed J, Shagrani M, Sant'Anna A. Role of wireless capsule endoscopy in reclassifying inflammatory bowel disease in children. J Pediatr (Rio J) 2013; 89 (02) 204-209
• 164 Monteiro S, Dias de Castro F, Boal Carvalho P. et al. Essential role of small bowel capsule endoscopy in reclassification of colonic inflammatory bowel disease type unclassified. World J Gastrointest Endosc 2017; 9 (01) 34-40
• 165 Gralnek IM, Defranchis R, Seidman E, Leighton JA, Legnani P, Lewis BS. Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. Aliment Pharmacol Ther 2008; 27 (02) 146-154
• 166 Cotter J, Dias de Castro F, Magalhães J, Moreira MJ, Rosa B. Validation of the Lewis score for the evaluation of small-bowel Crohn's disease activity. Endoscopy 2015; 47 (04) 330-335
• 167 Dias de Castro F, Boal Carvalho P, Monteiro S. et al. Lewis Score—prognostic value in patients with isolated small bowel Crohn's disease. J Crohn's Colitis 2015; 9 (12) 1146-1151
• 168 Monteiro S, Boal Carvalho P, Dias de Castro F. et al. Capsule endoscopy: diagnostic accuracy of Lewis score in patients with suspected Crohn's disease. Inflamm Bowel Dis 2015; 21 (10) 2241-2246
• 169 He C, Zhang J, Chen Z. et al. Relationships of capsule endoscopy Lewis score with clinical disease activity indices, C-reactive protein, and small bowel transit time in pediatric and adult patients with small bowel Crohn's disease. Medicine (Baltimore) 2017; 96 (33) e7780
• 170 Klang E, Amitai MM, Lahat A. et al; Israeli IBD research Nucleus [IIRN). Capsule endoscopy validation of the magnetic enterography global score in patients with established Crohn's disease. J Crohn's Colitis 2018; 12 (03) 313-320
• 171 Nishikawa T, Nakamura M, Yamamura T. et al. Lewis score on capsule endoscopy as a predictor of the risk for Crohn's disease-related emergency hospitalization and clinical relapse in patients with small bowel Crohn's disease. Gastroenterol Res Pract 2019; 2019: 4274257
• 172 Nishikawa T, Nakamura M, Yamamura T. et al. Lewis score on capsule endoscopy can predict the prognosis in patients with small bowel lesions of Crohn's disease. J Gastroenterol Hepatol 2021; 36 (07) 1851-1858
• 173 Gal E, Geller A, Fraser G, Levi Z, Niv Y. Assessment and validation of the new capsule endoscopy Crohn's disease activity index (CECDAI). Dig Dis Sci 2008; 53 (07) 1933-1937
• 174 Niv Y, Ilani S, Levi Z. et al. Validation of the Capsule Endoscopy Crohn's Disease Activity Index (CECDAI or Niv score): a multicenter prospective study. Endoscopy 2012; 44 (01) 21-26
• 175 Ponte A, Pinho R, Rodrigues A. et al. Evaluation and comparison of capsule endoscopy scores for assessment of inflammatory activity of small-bowel in Crohn's disease. Gastroenterol Hepatol 2018; 41 (04) 245-250
• 176 Koulaouzidis A, Douglas S, Plevris JN. Lewis score correlates more closely with fecal calprotectin than Capsule Endoscopy Crohn's Disease Activity Index. Dig Dis Sci 2012; 57 (04) 987-993
• 177 Miyazu T, Ishida N, Takano R. et al. Usefulness of the capsule endoscopy Crohn's disease activity index in assessing the necessity of early additional treatment in patients with Crohn's disease in clinical remission. Medicine (Baltimore) 2021; 100 (29) e26550
• 178 Niv Y, Gal E, Gabovitz V, Hershkovitz M, Lichtenstein L, Avni I. Capsule Endoscopy Crohn's Disease Activity Index (CECDAIic or Niv Score) for the Small Bowel and Colon. J Clin Gastroenterol 2018; 52 (01) 45-49
• 179 Arieira C, Magalhães R, Dias de Castro F. et al. CECDAIic - a new useful tool in pan-intestinal evaluation of Crohn's disease patients in the era of mucosal healing. Scand J Gastroenterol 2019; 54 (11) 1326-1330
• 180 Eliakim R, Yablecovitch D, Lahat A. et al. A novel PillCam Crohn's capsule score (Eliakim score) for quantification of mucosal inflammation in Crohn's disease. United European Gastroenterol J 2020; 8 (05) 544-551
• 181 Hosoe N, Nakano M, Takeuchi K. et al. Establishment of a novel scoring system for colon capsule endoscopy to assess the severity of Ulcerative Colitis-Capsule Scoring Of Ulcerative Colitis. Inflamm Bowel Dis 2018; 24 (12) 2641-2647
• 182 Macedo Silva V, Freitas M, Boal Carvalho P. et al. Apex Score: predicting flares in small-bowel Crohn's disease after mucosal healing. Dig Dis Sci 2022; 67 (04) 1278-1286
• 183 Jensen MD, Nathan T, Kjeldsen J. Inter-observer agreement for detection of small bowel Crohn's disease with capsule endoscopy. Scand J Gastroenterol 2010; 45 (7-8): 878-884
• 184 Kumar R, Zhao Q, Seshamani S, Mullin G, Hager G, Dassopoulos T. Assessment of Crohn's disease lesions in wireless capsule endoscopy images. IEEE Trans Biomed Eng 2012; 59 (02) 355-362
• 185 Charisis VS, Hadjileontiadis LJ. Potential of hybrid adaptive filtering in inflammatory lesion detection from capsule endoscopy images. World J Gastroenterol 2016; 22 (39) 8641-8657
• 186 Klang E, Barash Y, Margalit RY. et al. Deep learning algorithms for automated detection of Crohn's disease ulcers by video capsule endoscopy. Gastrointest Endosc 2020; 91 (03) 606-613.e2
• 187 Barash Y, Azaria L, Soffer S. et al. Ulcer severity grading in video capsule images of patients with Crohn's disease: an ordinal neural network solution. Gastrointest Endosc 2021; 93 (01) 187-192
• 188 Klang E, Grinman A, Soffer S. et al. Automated detection of Crohn's disease intestinal strictures on capsule endoscopy images using deep neural networks. J Crohn's Colitis 2021; 15 (05) 749-756
• 189 Klang E, Kopylov U, Mortensen B. et al. A convolutional neural network deep learning model trained on CD ulcers images accurately identifies NSAID ulcers. Front Med (Lausanne) 2021; 8: 656493
• 190 de Maissin A, Vallée R, Flamant M. et al. Multi-expert annotation of Crohn's disease images of the small bowel for automatic detection using a convolutional recurrent attention neural network. Endosc Int Open 2021; 9 (07) E1136-E1144
• 191 Ferreira JPS, de Mascarenhas Saraiva MJDQEC, Afonso JPL. et al. Identification of ulcers and erosions by the novel Pillcam™ Crohn's capsule using a convolutional neural network: a multicentre pilot study. J Crohn's Colitis 2022; 16 (01) 169-172
• 192 Higuchi N, Hiraga H, Sasaki Y. et al. Automated evaluation of colon capsule endoscopic severity of ulcerative colitis using ResNet50. PLoS One 2022; 17 (06) e0269728
• 193 Koulaouzidis A, Smirnidis A, Douglas S, Plevris JN. QuickView in small-bowel capsule endoscopy is useful in certain clinical settings, but QuickView with Blue Mode is of no additional benefit. Eur J Gastroenterol Hepatol 2012; 24 (09) 1099-1104
• 194 Halling ML, Nathan T, Kjeldsen J, Jensen MD. High sensitivity of quick view capsule endoscopy for detection of small bowel Crohn's disease. J Gastroenterol Hepatol 2014; 29 (05) 992-996
• 195 Tontini GE, Cavallaro F, Neumann H, Pastorelli L, Neurath MF, Spina L. et al. Extensive small-bowel Crohn's disease detected by the newly introduced 360° panoramic viewing capsule endoscopy system. Endoscopy 2014; 46 (Suppl 1 UCTN): E353-E354
• 196 Freitas M, Arieira C, Carvalho PB, Rosa B, Moreira MJ, Cotter J. Simplify to improve in capsule endoscopy—TOP 100 is a swift and reliable evaluation tool for the small bowel inflammatory activity in Crohn's disease. Scand J Gastroenterol 2020; 55 (04) 408-413
• 197 Nam SJ, Lim YJ, Nam JH. et al. 3D reconstruction of small bowel lesions using stereo camera-based capsule endoscopy. Sci Rep 2020; 10 (01) 6025
• 198 Tontini GE, Rizzello F, Cavallaro F. et al. Usefulness of panoramic 344°-viewing in Crohn's disease capsule endoscopy: a proof of concept pilot study with the novel PillCam™ Crohn's system. BMC Gastroenterol 2020; 20 (01) 97
• 199 Yung DE, Robertson AR, Davie M. et al. Double-headed small-bowel capsule endoscopy: real-world experience from a multi-centre British study. Dig Liver Dis 2021; 53 (04) 461-466
• 200 Oliva S, Cucchiara S, Spada C. et al. Small bowel cleansing for capsule endoscopy in paediatric patients: a prospective randomized single-blind study. Dig Liver Dis 2014; 46 (01) 51-55
• 201 Semenov S, Ismail MS, O'Hara F. et al. Addition of castor oil as a booster in colon capsule regimens significantly improves completion rates and polyp detection. World J Gastrointest Pharmacol Ther 2021; 12 (06) 103-112

Publikationsverlauf

Artikel online veröffentlicht:
23. Oktober 2023